<SEC-DOCUMENT>0001104659-23-072232.txt : 20230616
<SEC-HEADER>0001104659-23-072232.hdr.sgml : 20230616
<ACCEPTANCE-DATETIME>20230616160823
ACCESSION NUMBER:		0001104659-23-072232
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230615
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230616
DATE AS OF CHANGE:		20230616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Edgewise Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001710072
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				821725586
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40236
		FILM NUMBER:		231021116

	BUSINESS ADDRESS:	
		STREET 1:		1715 38TH ST
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		720-262-7002

	MAIL ADDRESS:	
		STREET 1:		1715 38TH ST
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2318809d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ewtx="http://edgewisetx.com/20230615">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ewtx_edgewisetx.com_20230615 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20230615_20230615 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001710072 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityCentralIndexKey">0001710072</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ewtx-20230615.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-06-15to2023-06-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001710072</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt"></p>

<p style="margin: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20230615__20230615_zbdyjULIw9Yf"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):<br />
<span id="xdx_908_edei--DocumentPeriodEndDate_c20230615__20230615_za6BBjaiicFh"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 15, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20230615__20230615_zjyGNoqFMd6"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityRegistrantName">Edgewise Therapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top; width: 34%; font-size: 10pt; text-align: center"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20230615__20230615_zuuerDQvzrV1" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_90B_edei--EntityFileNumber_c20230615__20230615_zZeQdE2c92uk" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityFileNumber">001-40236</ix:nonNumeric></span></b></td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20230615__20230615_zP4yHLVNzHv7" style="font-size: 10pt; background-color: white"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityTaxIdentificationNumber">82-1725586</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.5pt 3.5pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(IRS
    Employer<br />
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 1pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20230615__20230615_z2WZyCFUUqM5"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityAddressAddressLine1">1715
38th St.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20230615__20230615_zoKap0vopOrl"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityAddressCityOrTown">Boulder</ix:nonNumeric></span></b><b>,
<span id="xdx_907_edei--EntityAddressStateOrProvince_c20230615__20230615_zN1TpVMfEqXj"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityAddressStateOrProvince">CO</ix:nonNumeric></span></b><b> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20230615__20230615_z4LHHprhLvaa"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:EntityAddressPostalZipCode">80301</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices) (Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>(<span id="xdx_901_edei--CityAreaCode_c20230615__20230615_zIQteruTFDlc"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:CityAreaCode">720</ix:nonNumeric></span>)
</b><b><span id="xdx_902_edei--LocalPhoneNumber_c20230615__20230615_zUUSfz1UxaE8"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:LocalPhoneNumber">262-7002</ix:nonNumeric></span></b><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; white-space: nowrap; width: 5%; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20230615__20230615_z5GQxKcfhrH5" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; white-space: nowrap; width: 5%; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20230615__20230615_zHWxydNQXBG2" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; white-space: nowrap; width: 5%; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20230615__20230615_zJKDjIraZRo7" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt; white-space: nowrap; width: 5%; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20230615__20230615_zQzHXVFqfyOb" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt; font-size: 10pt"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c)) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding: 0.5pt 0.5pt 0.6pt; vertical-align: bottom; width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-bottom: white 1pt solid; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.5pt 0.5pt 0.6pt; vertical-align: bottom; width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-bottom: white 1pt solid; padding: 0.25pt 0.25pt 0.4pt; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.5pt 0.5pt 0.6pt; vertical-align: bottom; width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.6pt 0.5pt 0.5pt; font-size: 10pt; text-align: center"><span id="xdx_905_edei--Security12bTitle_c20230615__20230615_z07BYQKSxWK8" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.6pt 0.5pt 0.5pt; font-size: 10pt; text-align: center"><span id="xdx_909_edei--TradingSymbol_c20230615__20230615_zpuYLKWOUkKd" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" name="dei:TradingSymbol">EWTX</ix:nonNumeric></span></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.6pt 0.5pt 0.5pt; font-size: 10pt; text-align: center"><span id="xdx_90A_edei--SecurityExchangeName_c20230615__20230615_zGKzFWWdeHRg" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Global Select Market</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20230615__20230615_z4exWlMyusYi" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span id="xdx_900_edei--EntityExTransitionPeriod_c20230615__20230615_zHK23GO6QdV5" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2023-06-15to2023-06-15" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="margin: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">On June 16, 2023, Edgewise Therapeutics, Inc. (the
&#8220;Company&#8221;) entered into a Sales Agreement (the &#8220;Sales Agreement&#8221;) with BofA Securities, Inc. (&#8220;BofA
Securities&#8221;) under which the Company may offer and sell shares of the Company&#8217;s common stock, par value $0.0001 per
share (the &#8220;Common Stock&#8221;), having aggregate sales proceeds of up to $125,000,000 (the &#8220;Shares&#8221;), from time to time, through an
&#8220;at the market offering&#8221; program under which BofA Securities will act as sales agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">Under the Sales Agreement, the Company will set the
parameters for the sale of the Shares, including the number or dollar value of Shares to be issued, the time period during which
sales are requested to be made, limitations on the number of Shares that may be sold in any one trading day and any minimum price
below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, BofA Securities may sell the Shares
by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of
1933, as amended. BofA Securities agreed to use commercially reasonable efforts in conducting such sales activities consistent with
its normal trading and sales practices, applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global
Select Market LLC. The Sales Agreement may be terminated by the Company upon ten days&#8217; notice to BofA Securities for any
reason or by BofA Securities upon ten days&#8217; notice to the Company for any reason, or immediately under certain circumstances,
including but not limited to the occurrence of a material adverse change in the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">The Sales Agreement provides that BofA Securities will be
entitled to compensation for its services in an amount up to 3.0% of the gross proceeds of all Shares sold under the Sales Agreement. The Company has no obligation to sell any Shares under the Sales Agreement and may at any time suspend
solicitation and offers under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">The Shares will be issued pursuant to the Company&#8217;s
shelf registration statement on Form S-3 (File No. 333-264083), filed with the Securities and Exchange Commission on April 1, 2022 (the &#8220;Registration Statement&#8221;) and declared effective on May 5, 2022. On June 16, 2023, the Company filed
a prospectus supplement with the Commission in connection with the offer and sale of the Shares pursuant to the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">The foregoing description of the Sales Agreement is not complete
and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to
this Current Report on Form 8-K (this &#8220;Current Report&#8221;) and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">The legal opinion of Wilson Sonsini Goodrich &amp;
Rosati, Professional Corporation, relating to the Common Stock being offered pursuant to the Sales Agreement is filed as Exhibit 5.1
to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">This Current Report shall not constitute an offer to sell
or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws
of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0"><b>Item 1.02 Termination of a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">As previously disclosed, on April 1, 2022, the Company entered
into a Sales Agreement (the &#8220;Prior Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), <span style="background-color: white">as
agent</span>, pursuant to which the Company was permitted to issue and sell shares of its Common Stock, having
an aggregate offering price of up to $125,000,000 (the &#8220;Placement Shares&#8221;), from time to time through Cowen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">In connection with the Company&#8217;s entry into the Sales
Agreement, on June 15, 2023, the Company delivered written notice to Cowen to terminate the Prior Sales Agreement pursuant to Section
11(b) thereof. Prior to termination, the Company had not sold any Placement Shares under the Prior Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">A copy of the Prior Sales Agreement was filed as Exhibit
1.2 to the Registration Statement. The description of the Prior Sales Agreement contained
in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Prior
Sales Agreement filed as Exhibit 1.2 to the Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding: 0.25pt; white-space: nowrap; width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; width: 89%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
<tr>
<td style="padding: 0.25pt; font-size: 10pt"><a href="tm2318809d2_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><a href="tm2318809d2_ex1-1.htm" style="-sec-extract: exhibit">Sales Agreement, dated June 16, 2023, by and between Edgewise Therapeutics, Inc. and BofA
Securities, Inc.</a></td></tr>
<tr>
<td style="padding: 0.25pt; font-size: 10pt"><a href="tm2318809d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td>&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><a href="tm2318809d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation</span></a></td></tr>
<tr>
<td style="padding: 0.25pt"><a href="tm2318809d2_ex5-1.htm" style="-sec-extract: exhibit">23.1 &#160;</a></td>
    <td>&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><a href="tm2318809d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation (included with the opinion filed as Exhibit 5.1)</span></a></td></tr>
<tr>
<td style="padding: 0.25pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
<td style="padding: 0.25pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 172.65pt 0pt 243.25pt; text-align: center; color: #231f20"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Edgewise Therapeutics, Inc.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;June 16, 2023</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top">/s/ <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Koch<span style="text-decoration: underline"></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Koch</span></td></tr>
  <tr>
    <td style="width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.3pt 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk1TFOmjRUWsIkXE12i3EmyzZRP/juQtjS3isrAsM9+MEAOxpIWpkeE4K3LYY9PW2iMUWCGjPWNwZKt1CuEWeDHOs7a+e39gRoHBwIyHcXIKQme9G4dlCnIyUslIKZDTVCaw24joq2dkK1Oi9UbXoG0JO6aWDXrNrz5hr59kqXl1VQdkZ8imEA9lL79ByVjBlu76QXx1kOeZiAbdRGLJdGu/NTfnqYF5jU3ocj363+gDGRRJSw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2318809d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Edgewise
Therapeutics,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>$125,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Common
stock<BR>
SALES AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">June&nbsp;16, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Edgewise Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;<B><U>Company</U></B>&rdquo;), confirms its agreement (this &ldquo;<B><U>Agreement</U></B>&rdquo;)
with BofA Securities,&nbsp;Inc. (&ldquo;<B><U>BofA</U></B>&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the
conditions set forth herein, it may issue and sell through BofA, acting as agent and/or principal, shares (the &ldquo;<B><U>Placement
Shares</U></B>&rdquo;) of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;<B><U>Common Stock</U></B>&rdquo;),
having an aggregate offering price of up to $125,000,000 (the &ldquo;<B><U>Maximum Amount</U></B>&rdquo;). Notwithstanding anything to
the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this <U>Section&nbsp;1</U> on
the number of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and BofA shall
have no obligation in connection with such compliance. The issuance and sale of Placement Shares through BofA will be effected pursuant
to the Registration Statement (as defined below) filed by the Company, which such Registration Statement was declared effective by the
Securities and Exchange Commission (the &ldquo;<B><U>Commission</U></B>&rdquo;) on May&nbsp;5, 2022, although nothing in this Agreement
shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has filed, in
accordance with the provisions of the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder (collectively,
the &ldquo;<B><U>Securities Act</U></B>&rdquo;), with the Commission a registration statement on Form&nbsp;S-3, including a base prospectus,
relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference
documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended,
and the rules&nbsp;and regulations thereunder (collectively, the &ldquo;<B><U>Exchange Act</U></B>&rdquo;). The Company has prepared a
prospectus supplement specifically relating to the Placement Shares (the &ldquo;<B><U>Prospectus Supplement</U></B>&rdquo;) to the base
prospectus included as part of such registration statement. The Company shall furnish to BofA, for use by BofA, copies of the prospectus
included as part of such registration statement, as supplemented by the Prospectus Supplement relating to the Shares. Except where the
context otherwise requires, such registration statement, and any post-effective amendment thereto, as amended when it becomes effective,
including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus
(as defined below) subsequently filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act or deemed to be a
part of such registration statement pursuant to Rule&nbsp;430B or 462(b)&nbsp;of the Securities Act, or any subsequent registration statement
on Form&nbsp;S-3 filed pursuant to Rule&nbsp;415(a)(6)&nbsp;under the Securities Act by the Company to cover any Shares, is herein called
the &ldquo;<B><U>Registration Statement.</U></B>&rdquo; The base prospectus, including all documents incorporated therein by reference,
included in the Registration Statement, as it may be supplemented by the Prospectus Supplement in the form in which such prospectus and/or
Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities
Act, together with any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433 of the Securities Act regulations (&ldquo;<B><U>Rule&nbsp;433</U></B>&rdquo;<B>)</B>,
relating to the Shares that (i)&nbsp;is consented to by BofA, hereinafter referred to as a &ldquo;<B><U>Permitted Free Writing Prospectus</U></B>,&rdquo;
(ii)&nbsp;is required to be filed with the Commission by the Company or (iii)&nbsp;is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i),
in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the
Company&rsquo;s records pursuant to Rule&nbsp;433(g), is herein called the &ldquo;<B><U>Prospectus</U></B>.&rdquo; Any reference herein
to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents
incorporated by reference therein, including, unless the context otherwise requires, the documents, if any, filed as exhibits to such
incorporated documents, and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo;
with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof
of any document with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to
the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the
Commission pursuant to the Electronic Data Gathering Analysis and Retrieval System or any successor thereto (collectively, &ldquo;<B><U>EDGAR</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Placements</U>.
Each time that the Company wishes to issue and sell the Placement Shares hereunder (each, a &ldquo;<B><U>Placement</U></B>&rdquo;), it
will notify BofA by email notice (or other method mutually agreed to in writing by the parties) (a &ldquo;<B><U>Placement Notice</U></B>&rdquo;)
containing the parameters in accordance with which it desires the Placement Shares to be sold, which shall at a minimum include the number
of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement
Shares that may be sold in any one Trading Day (as defined in <U>Section&nbsp;3</U>) and any minimum price below which sales may not be
made, a form of which containing such minimum sales parameters necessary is attached hereto as <B><U>Schedule 1</U></B>. The Placement
Notice shall originate from any of the individuals from the Company set forth on <B><U>Schedule 2</U></B> (with a copy to each of the
other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from BofA set forth on
<B><U>Schedule 2</U></B>, as such <B><U>Schedule 2</U></B> may be amended from time to time in accordance herewith. The Placement Notice
shall be effective upon receipt by BofA unless and until (i)&nbsp;in accordance with the notice requirements set forth in <U>Section&nbsp;4</U>,
BofA declines to accept the terms contained therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of the Placement
Shares have been sold, (iii)&nbsp;in accordance with the notice requirements set forth in <U>Section&nbsp;4</U>, the Company suspends
or terminates the Placement Notice for any reason in its sole discretion, (iv)&nbsp;the Company issues a subsequent Placement Notice with
parameters superseding or amending those on the earlier dated Placement Notice for any reason in its sole discretion, or (v)&nbsp;this
Agreement has been terminated under the provisions of <U>Section&nbsp;11</U>. The amount of any discount, commission or other compensation
to be paid by the Company to BofA in connection with the sale of the Placement Shares shall be calculated in accordance with the terms
set forth in <B><U>Schedule 3</U>.</B> It is expressly acknowledged and agreed that neither the Company nor BofA will have any obligation
whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to BofA and BofA
does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein.
In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice
will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sale
of Placement Shares by BofA.</U> Subject to the terms and conditions herein set forth, upon the Company&rsquo;s delivery of a Placement
Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance
with the terms of this Agreement, BofA, for the period specified in the Placement Notice, will use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable state and federal laws, rules&nbsp;and regulations and the rules&nbsp;of
the Nasdaq Stock Market,&nbsp;Inc. (&ldquo;<B><U>Nasdaq</U></B>&rdquo;) to sell such Placement Shares up to the amount specified, and
otherwise in accordance with the terms of such Placement Notice. BofA will provide written confirmation to the Company (including by email
correspondence to each of the individuals of the Company set forth on <B><U>Schedule 2</U></B>, if receipt of such correspondence is actually
acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading
Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the
number of Placement Shares sold on such day, the volume-weighted average price of the Placement Shares sold, and the Net Proceeds (as
defined below) payable to the Company. In the event the Company engages BofA for a sale of Placement Shares that would constitute a &ldquo;block&rdquo;
within the meaning of Rule&nbsp;10b-18(a)(5)&nbsp;under the Exchange Act, the Company will provide BofA, at BofA&rsquo;s request and upon
reasonable advance notice to the Company, on or prior to the Settlement Date (as defined below), the opinions of counsel, accountant&rsquo;s
letter and officers&rsquo; certificates set forth in <U>Section&nbsp;8</U> hereof, each dated the Settlement Date, and such other documents
and information as BofA shall reasonably request. BofA may sell Placement Shares by any method permitted by law deemed to be an &ldquo;at
the market&rdquo; offering as defined in Rule&nbsp;415(a)(4)&nbsp;under the Securities Act, including without limitation sales made through
Nasdaq or on any other existing trading market for the Common Stock. BofA may sell Placement Shares in negotiated transactions only if
expressly authorized by the Company in a Placement Notice. BofA shall not purchase Placement Shares for its own account as principal unless
expressly authorized to do so by the Company in a Placement Notice. The Company acknowledges and agrees that (i)&nbsp;there can be no
assurance that BofA will be successful in selling Placement Shares, and (ii)&nbsp;BofA will incur no liability or obligation to the Company
or any other person or entity if it does not sell Placement Shares for any reason other than a failure by BofA to use its commercially
reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares as required under this <U>Section&nbsp;3</U>.
For the purposes hereof, &ldquo;<B><U>Trading Day</U></B>&rdquo; means any day on which the Company&rsquo;s Common Stock is purchased
and sold on the principal market on which the Common Stock is listed or quoted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any other provision of this Agreement,
the Company shall not offer, sell or deliver, or request the offer or sale, of any Placement Shares pursuant to this Agreement and, by
notice to BofA given by telephone (confirmed promptly by email), shall cancel any instructions for the offer or sale of any Placement
Shares, and BofA shall not be obligated to offer or sell any Placement Shares, (i)&nbsp;during any period in which the Company is, or
would reasonably be deemed to be, in possession of material non-public information, or (ii)&nbsp;at any time from and including the date
on which the Company shall issue a press release containing, or shall otherwise publicly announce, its earnings, revenues or other results
of operations (an &ldquo;<B><U>Earnings Announcement</U></B>&rdquo;) through and including the time that the Company files a Quarterly
Report on Form&nbsp;10-Q or an Annual Report on Form&nbsp;10-K that includes consolidated financial statements as of and for the same
period or periods, as the case may be, covered by such Earnings Announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Suspension
of Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company or BofA may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other
party set forth on <B><U>Schedule 2</U></B>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom
the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence
to each of the individuals of the other party set forth on <B><U>Schedule 2</U></B>), suspend any sale of Placement Shares; <I>provided,
however</I>, that such suspension shall not affect or impair either party&rsquo;s obligations with respect to any Placement Shares sold
hereunder prior to the receipt of such notice. While a suspension is in effect, any obligation under <U>Sections 7(m)</U>, <U>7(n)</U>&nbsp;and
<U>7(o)</U>&nbsp;with respect to delivery of certificates, opinion, or comfort letters to BofA shall be waived. Each of the parties agrees
that no such notice under this <U>Section&nbsp;4</U> shall be effective against the other unless it is made to one of the individuals
named on <B><U>Schedule 2</U></B> hereto, as such schedule may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
either BofA or the Company has reason to believe that the exemptive provisions set forth in Rule&nbsp;101(c)(1)&nbsp;of Regulation M under
the Exchange Act are not satisfied with respect to the Common Stock, it shall promptly notify the other party, and BofA may, at its sole
discretion, suspend sales of the Placement Shares under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
any other provision of this Agreement, during any period in which the Registration Statement is not effective under the Securities Act,
the Company shall promptly notify BofA, the Company shall not request the sale of any Placement Shares, and BofA shall not be obligated
to sell or offer to sell any Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Settlement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Settlement
of Placement Shares</U>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will
occur on the second (2<SUP>nd</SUP>) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date
on which such sales are made (each, a &ldquo;<B><U>Settlement Date</U></B>&rdquo; and the first such settlement date, the &ldquo;<B><U>First
Delivery Date</U></B>&rdquo;). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement
Shares sold (the &ldquo;<B><U>Net Proceeds</U></B>&rdquo;) will be equal to the aggregate sales price received by BofA at which such Placement
Shares were sold, after deduction for (i)&nbsp;BofA&rsquo;s commission, discount or other compensation for such sales payable by the Company
pursuant to <U>Section&nbsp;2</U> hereof, (ii)&nbsp;any other amounts, if any, due and payable by the Company to BofA hereunder pursuant
to <U>Section&nbsp;7(g)</U>&nbsp;(Expenses) hereof, and (iii)&nbsp;any transaction fees imposed by any governmental or self-regulatory
organization in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer
the Placement Shares being sold by crediting BofA&rsquo;s or its designee&rsquo;s account (provided BofA shall have given the Company
written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit
and Withdrawal at Custodian System (&ldquo;<B><U>DWAC</U></B>&rdquo;) or by such other means of delivery as may be mutually agreed upon
by the parties hereto which in all cases shall be freely tradeable, transferable, registered shares in good deliverable form. On each
Settlement Date, BofA will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to,
the Settlement Date. BofA will be responsible for providing DWAC instructions or instructions by other means with regard to the transfer
of the Placement Shares being sold. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation
to deliver duly authorized Placement Shares on a Settlement Date through no fault of BofA, the Company agrees that in addition to and
in no way limiting the rights and obligations set forth in <U>Section&nbsp;9(a)</U>&nbsp;(Indemnification and Contribution) hereto, it
will (i)&nbsp;hold BofA harmless against any loss, claim, damage, or reasonable and documented expense (including reasonable and documented
legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii)&nbsp;pay to BofA (without
duplication) any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as disclosed in the Registration Statement or the Prospectus, the Company represents and warrants
to, and agrees with, BofA that, unless such representation, warranty or agreement specifies a different time, as of (i)&nbsp;the date
of this Agreement, (ii)&nbsp;each Time of Sale (as defined below), (iii)&nbsp;each Settlement Date, and (iv)&nbsp;each Bring-Down Date
(as defined below) (each date included in (i)&nbsp;through (iv), a &ldquo;<B><U>Representation Date</U></B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Registration Requirements</U>. Prior to the issuance of any Placement Notice by the Company, the Registration Statement and any registration
statement filed pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act with respect to the Registration Statement (a &ldquo;<B><U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U></B>&rdquo;), will have been declared effective by the Commission under the Securities Act. The Company has complied to the
Commission&rsquo;s satisfaction with all requests of the Commission for additional or supplemental information with respect to the Registration
Statement. No stop order suspending the effectiveness of the Registration Statement or any Rule&nbsp;462(b)&nbsp;Registration Statement
is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, contemplated
or threatened by the Commission. </FONT>The Company meets the requirements for use of Form&nbsp;S-3 under the Securities Act. The sale
of the Placement Shares hereunder meets the requirements of General Instruction I.B.1 of Form&nbsp;S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Misstatement or Omission</U>. The Prospectus when filed complied and, as amended or supplemented, if applicable, will comply in all material
respects with the Securities Act. Each of the Registration Statement, any Rule&nbsp;462(b)&nbsp;Registration Statement, the Prospectus
and any post-effective amendments or supplements thereto, at the time it became effective or its date, as applicable, complied and as
of each Representation Date, complied and will comply in all material respects with the Securities Act and did not and, as of each Representation
Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date, did not and, as
of each Representation Date, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and
warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement,
any Rule&nbsp;462(b)&nbsp;Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements
thereto, made in reliance upon and in conformity with information relating to Agent&rsquo;s Information (as defined below). There are
no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which
have not been described or filed as required. As used herein, &ldquo;<B><U>Time of Sale</U></B>&rdquo; means with respect to each offering
of Placement Shares pursuant to this Agreement, the time of BofA&rsquo;s initial entry into contracts with purchasers for the sale of
such Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Offering
Materials Furnished to BofA</U>. The Company has delivered to BofA one complete copy of the Registration Statement and a copy of each
consent and certificate of experts filed as a part thereof, and conformed copies of the Registration Statement (without exhibits) and
the Prospectus, as amended or supplemented, in such quantities and at such places as BofA has reasonably requested. The Registration Statement,
the Prospectus and any Permitted Free Writing Prospectus (to the extent any such Permitted Free Writing Prospectus was required to be
filed with the Commission) delivered to BofA for use in connection with the public offering of the Placement Shares contemplated herein
have been and will be identical to the versions of such documents transmitted to the Commission for filing via EDGAR, except to the extent
permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Emerging Growth
Company</U>. From the time of initial confidential submission of the Registration Statement to the Commission, the Company has been and
is an &ldquo;emerging growth company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &ldquo;<B><U>Emerging Growth
Company</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Financial Statements</U>. The financial statements (including the related notes thereto) of the Company and its subsidiaries
included in or incorporated by reference in the Registration Statement and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Exchange Act, as applicable, and present fairly, in all material respects, the financial position
of the Company as of the dates indicated and the results of its operations and the changes in its cash flows for the periods specified;
such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&ldquo;<B><U>GAAP</U></B>&rdquo;)
applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited financial statements, which are
subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules&nbsp;of the Commission.
The supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the
information required to be stated therein; the other financial information included or incorporated by reference in the Registration Statement
and the Prospectus has been derived from the accounting records of the Company and its subsidiaries and presents fairly in all material
respects the information shown thereby; and all disclosures included or incorporated by reference in the Registration Statement and the
Prospectus regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the Commission)
comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>No Material Adverse Change</U>. </FONT>Since the date of the most recent financial statements of the Company included or incorporated
by reference in the Registration Statement and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than
the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, the grant of options and
awards under existing equity incentive plans described in, and the issuance of any stock upon conversion of the Company&rsquo;s securities
described in the Registration Statement and the Prospectus, and the repurchase of shares of capital stock pursuant to agreements providing
for an option to repurchase or a right of first refusal on behalf of the Company pursuant to the Company&rsquo;s repurchase rights), any
material change in short-term debt or long-term debt of the Company and its subsidiaries, or any dividend or distribution of any kind
declared, set aside for payment, paid or made by the Company or its subsidiaries on any class of capital stock, or any material adverse
change, or any development that would reasonably be expected to result in a Material Adverse Effect (as defined in Section&nbsp;6(g)&nbsp;below);
(ii)&nbsp;the Company and each of its subsidiaries has not entered into any transaction or agreement (whether or not in the ordinary course
of business) that is material to the Company or incurred any liability or obligation, direct or contingent, that is material to the Company;
and (iii)&nbsp;the Company and each of its subsidiaries has not sustained any loss or interference with its business that is material
to the Company and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each
case as otherwise disclosed in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Organization and Good Standing</U><I>.</I> The Company has been duly organized and is validly existing and in good standing
under the laws of its jurisdictions of organization, is duly qualified to do business and is in good standing in each jurisdiction in
which its ownership or lease of property or the conduct of its business requires such qualification, and has all power and authority necessary
to own or hold its properties and to conduct the business in which it is engaged, except where the failure to be so qualified or in good
standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse
effect on the business, properties, management, financial position, stockholders&rsquo; equity, results of operations or prospects of
the Company or on the performance by the Company of its obligations under this Agreement (a &ldquo;<B><U>Material Adverse Effect</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsidiaries</U><I>.</I>
To the extent applicable, each subsidiary of the Company (each a &ldquo;Subsidiary&rdquo; has been duly organized and is validly existing
as a corporation or limited liability company in good standing under the laws of the jurisdiction of its organization and has the requisite
power and authority to own, lease and operate its properties and to conduct its business as described in the Prospectus. To the extent
applicable, the Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries
listed in Exhibit&nbsp;21.1 to the Company&rsquo;s Annual Report on Form&nbsp;10-K for the most recently ended fiscal year and other than
(i)&nbsp;those subsidiaries not required to be listed on Exhibit&nbsp;21.1 by Item 601 of Regulation S-K under the Exchange Act and (ii)&nbsp;those
subsidiaries formed since the last day of the most recently ended fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Capitalization</U><I>.</I> The Company has an authorized capitalization as set forth in the Registration Statement and the Prospectus
under the heading &ldquo;Description of Capital Stock&rdquo;; all the outstanding shares of capital stock of the Company have been duly
and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that
have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement and the Prospectus,
there are no outstanding rights (including, without limitation, pre-emptive rights that have not been duly waived or satisfied), warrants
or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the
Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance
of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options; the capital
stock of the Company and its subsidiaries conforms in all material respects to the description thereof contained in the Registration Statement
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Stock Options</U><I>. </I></FONT>With respect to the stock options (the &ldquo;<B><U>Stock Options</U></B>&rdquo;) granted pursuant
to the stock-based compensation plans of the Company (the &ldquo;<B><U>Company Stock Plans</U></B>&rdquo;), (i)&nbsp;each grant of a Stock
Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary
corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee
thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing
such grant (if any), to the Company&rsquo;s knowledge, was duly executed and delivered by each party thereto, (ii)&nbsp;each such grant
was made in all material respects in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws
and regulatory rules&nbsp;or requirements and (iii)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial
statements (including the related notes) of the Company and disclosed in the Company&rsquo;s filings with the Commission in accordance
with the Exchange Act, as applicable, and other applicable laws to the extent such disclosure is required under the Exchange Act and other
applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Due Authorization</U><I>.</I>
The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all
action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation
by it of the transactions contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Sales Agreement</U><I>.
</I> This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable
in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement
hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights
and remedies of creditors or by general equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>The Placement Shares</U><I>. </I>The Placement Shares to be issued and sold by the Company hereunder have been duly authorized
by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and
nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement and the Prospectus;
and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Listing</U></FONT>. The Company is subject to and in compliance in all material respects with the reporting requirements of Section&nbsp;13
or Section&nbsp;15(d)&nbsp;of the Exchange Act. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or Section&nbsp;12(g)&nbsp;of
the Exchange Act and is listed on the Nasdaq Global Select Market (the &ldquo;<B><U>Nasdaq Market</U></B>&rdquo;), and the Company has
taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange
Act or delisting the Common Stock from the Exchange, nor has the Company received any notification that the Commission or Nasdaq is contemplating
terminating such registration or listing. All of the Placement Shares that have been or may be sold under this Agreement have been approved
for listing on the Nasdaq, subject to official notice of issuance; the Company has taken all necessary actions to ensure that, upon and
at all times after the Nasdaq shall have approved the Placement Shares for listing, it will be in compliance with all applicable corporate
governance requirements set forth in the Nasdaq&rsquo;s listing rules&nbsp;that are then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; <U>Descriptions
of the Sales Agreement</U><I>.</I> This Agreement conforms in all material respects to the description thereof contained in the Registration
Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Violation or Default</U><I>.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter
or by-laws or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or
both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company is a party or by which the Company is bound
or to which any property or asset of the Company is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order,
rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority, having jurisdiction over the Company, except,
in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such default or violation that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Conflicts</U><I>. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of
the Placement Shares and the consummation of the transactions contemplated by this Agreement or the Prospectus will not (i)&nbsp;conflict
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination,
modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or
asset of the Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company is a party or by which the Company or its subsidiaries are bound or to which any property, right or asset of the Company or any
of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or by-laws or similar organizational
documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order,
rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority, having jurisdiction over the Company or any
of its subsidiaries, except, in the case of clauses (i)&nbsp;and (iii)&nbsp;above, for any such conflict, breach, violation, default,
lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>No Consents Required</U><I>.</I></FONT> No consent, filing, approval, authorization, order, license, registration or qualification
of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by
the Company of this Agreement, the issuance and sale of the Placement Shares and the consummation of the transactions contemplated by
this Agreement, except for (i)&nbsp;the registration of the Placement Shares under the Securities Act, (ii)&nbsp;such consents, approvals,
authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;<B><U>FINRA</U></B>&rdquo;) or the Nasdaq Market and under applicable state securities laws in connection with the purchase and
distribution of the Placement Shares, and (iii)&nbsp;those that have already been obtained or waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Legal Proceedings</U><I>.</I> Except as described in the Registration Statement and the Prospectus, there are no legal, governmental
or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&ldquo;<B><U>Actions</U></B>&rdquo;)
pending to which the Company or any of its subsidiaries are, or to the knowledge of the Company, may reasonably be expected to become
a party or to which any property of the Company or any of its subsidiaries are subject that, individually or in the aggregate, if determined
adversely to the Company, would reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions
are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current
or pending Actions that are required under the Securities Act to be described in the Registration Statement or the Prospectus that are
not so described in the Registration Statement and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other
documents that are required under the Securities Act to be filed or incorporated by reference as exhibits to the Registration Statement
or described in the Registration Statement or the Prospectus that are not so filed or incorporated by reference as exhibits to the Registration
Statement or described in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Independent Accountants</U>. </FONT>KPMG LLP, who has certified certain financial statements of the Company, is an independent registered
public accounting firm with respect to the Company within the applicable rules&nbsp;and regulations adopted by the Commission and the
Public Company Accounting Oversight Board (United States) and as required by the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Title to Real and Personal Property</U>. The Company and its subsidiaries have good and marketable title in fee simple (in the
case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to
the business of the Company and its subsidiaries (other than with respect to Intellectual Property, title to which is addressed exclusively
in Section&nbsp;6(v)), in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those
that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company or (ii)&nbsp;would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Intellectual Property</U><I>.</I> The Company and its subsidiaries own or have valid and enforceable licensed rights to use
all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress,
designs, data, database rights,&nbsp;Internet domain names, copyrights, works of authorship, licenses, proprietary information and know-how
(including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), and
all other intellectual property and proprietary rights, including registrations and applications for registration thereof necessary for
the conduct of its business as currently conducted and as proposed to be conducted, and which are described in the Registration Statement
and the Prospectus as being owned by or licensed to the Company and its subsidiaries (collectively, &ldquo;<B><U>Intellectual Property</U></B>&rdquo;).
To the Company&rsquo;s knowledge, the Company&rsquo;s and its subsidiaries&rsquo;conduct of its business does not and will not infringe,
misappropriate or otherwise violate the Intellectual Property of any third party. The Intellectual Property of the Company and its subsidiaries
have not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware
of any facts which would form a reasonable basis for any such adjudication. Neither the Company nor any of its subsidiaries have received
any notice of any claim of infringement, misappropriation or conflict with any intellectual property rights of another, and the Company
is unaware of any facts which would form a reasonable basis for any such notice or claim. To the Company&rsquo;s knowledge, (i)&nbsp;there
are no third parties who have rights to any Intellectual Property, except for the rights of third-party licensors; and (ii)&nbsp;there
is no infringement by third parties of any Intellectual Property. Except as disclosed in the Registration Statement and the Prospectus,
there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging
the Company&rsquo;s or its subsidiaries&rsquo; rights in or to any Intellectual Property, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope
of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding
or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringe, misappropriate, or otherwise violate, or would,
upon the commercialization of any product or service described in the Registration Statement and the Prospectus as under development,
infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the
terms of each agreement pursuant to which Intellectual Property has been licensed to the Company, and all such agreements are in full
force and effect. To the Company&rsquo;s knowledge, there are no material defects in any of the patents or patent applications included
in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their
Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements
and invention assignments with their employees, and to the Company&rsquo;s knowledge no employee of the Company or its subsidiaries is
in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee&rsquo;s employment with the Company. The duty of candor and good faith as required by the United
States Patent and Trademark Office during the prosecution of the United States patents and patent applications within the Intellectual
Property have been complied with for the Company-owned Intellectual Property; and in all foreign offices having similar requirements,
all such requirements have been complied with for the Company-owned Intellectual Property. None of the Company-owned Intellectual Property
or technology (including information technology and outsourced arrangements) employed by the Company or any of its subsidiaries has been
obtained or is being used by the Company or its subsidiaries in violation of any contractual obligation binding on the Company or its
subsidiaries, or any of its officers, directors or employees or otherwise in violation of the rights of any persons. The product candidates
described in the Registration Statement and the Prospectus as under development by the Company and its subsidiaries fall within the scope
of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Trade Secrets</U>. The Company and its subsidiaries have taken reasonable actions to protect its rights in and prevent the unauthorized
use and disclosure of material trade secrets and confidential business information (which may include confidential source code, ideas,
research and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications, research records,
records of inventions, test information, financial, marketing and business data, customer and supplier lists and information, pricing
and cost information, business and marketing plans and proposals) owned by the Company, and, to the knowledge of the Company, there has
been no unauthorized use or disclosure of material trade secrets and confidential business information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>
 &nbsp;<U>IT Assets</U>.&nbsp;(i)&nbsp;Except as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect, the computers, software, servers, networks, data communications lines, and other information technology systems owned,
licensed, leased or otherwise used by the Company and its subsidiaries (excluding any public networks) (collectively, the &ldquo;<B><U>IT
Assets</U></B>&rdquo;) operate and perform as is necessary for the operation of the business of the Company and its subsidiaries as currently
conducted as described in the Registration Statement and the Prospectus, and to the Company&rsquo;s knowledge, such IT Assets are not
infected by viruses, disabling code or other harmful code; and (ii)&nbsp;the Company and its subsidiaries have at all times implemented
and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their confidential information
and the integrity, continuous operation, redundancy and security of all IT Assets and all Personal Data (defined below) sensitive, confidential
or regulated data used in their businesses and within their possession or otherwise in their operational control, and to the knowledge
of the Company, there have been no breaches, violations, outages or unauthorized uses of or accesses to same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Data Privacy and Security Laws</U>. The Company and each of its subsidiaries are, and at all prior times was, in compliance
with all applicable state and federal data privacy and security laws and regulations, including without limitation, as applicable, the
Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B><U>HIPAA</U></B>&rdquo;) as amended by the Health Information
Technology for Economic and Clinical Health Act (the &ldquo;<B><U>HITECH Act</U></B>&rdquo;) and the European Union General Data Protection
Regulation (&ldquo;<B><U>GDPR</U></B>&rdquo;) (EU 2016/679) (collectively, the &ldquo;<B><U>Privacy Laws</U></B>&rdquo;), except to the
extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
The Company has in place, complies with, and takes reasonable steps to ensure compliance with its policies and procedures relating to
data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &ldquo;<B><U>Policies</U></B>&rdquo;).
 &ldquo;Personal Data&rdquo; means, as applicable, (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, e-mail address,
photograph, social security number or tax identification number, driver&rsquo;s license number, passport number, credit card number,
bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying information&rdquo;
under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv)&nbsp;&ldquo;personal
data&rdquo; as defined by GDPR; and (v)&nbsp;any other piece of information that allows the identification of such natural person, or
his or her family, or permits the collection or analysis of any data related to an identified person&rsquo;s health or sexual orientation.
The Company and its subsidiaries have, at all times, made all disclosures to users or customers required by applicable Privacy Laws,
and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable Privacy Laws, except
in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and
each of its subsidiaries: (i)&nbsp;has not received written notice of any actual or potential liability under or relating to, or actual
or potential violation by the Company of, any of the Privacy Laws and has no knowledge of any event or condition that would reasonably
be expected to result in any such notice; (ii)&nbsp;is not currently conducting or paying for, in whole or in part, any investigation,
remediation, or other corrective action required by any governmental entity pursuant to any Privacy Law; (iii)&nbsp;has made all notices
to all persons, including affected individuals and applicable governmental or regulatory authorities, required under any Privacy Law
with respect to the use, disclosure or breaches of Personal Data; or (iv)&nbsp;is not a party to any order, decree, or settlement agreement
that imposes any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Complaints</U>. To the Company&rsquo;s knowledge, there is no complaint to or audit, proceeding, investigation (formal or
informal) or claim currently pending against the Company by the Federal Trade Commission, the U.S. Department of Health and Human Services
and any office contained therein (&ldquo;<B><U>HHS</U></B>&rdquo;), or any similar authority in any jurisdiction other than the United
States or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company
or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>FDA Compliance</U>. The Company and each of its subsidiaries: (A)&nbsp;is and at all times has been in material compliance with
all statutes, rules&nbsp;or regulations of the U.S. Food and Drug Administration (the &ldquo;<B><U>FDA</U></B>&rdquo;) and other comparable
governmental entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed
by the Company (&ldquo;<B><U>Applicable Laws</U></B>&rdquo;); (B)&nbsp;has not received any FDA Form&nbsp;483, notice of adverse finding,
warning letter, untitled letter or other written correspondence or written notice from the FDA or any governmental entity alleging or
asserting a material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B><U>Authorizations</U></B>&rdquo;); (C)&nbsp;possesses
all Authorizations and such Authorizations are valid and in full force and effect and the Company is not in violation of any material
term of any such Authorizations; (D)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation
or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any governmental entity or third
party is threatening any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has not received written
notice that the FDA or any governmental entity has taken, is taking or intends to take action to suspend, modify or revoke any Authorizations
and has no knowledge that the FDA or any governmental entity is threatening such action, except in each case as would not, individually
or in the aggregate, have a Material Adverse Effect; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and, to the knowledge of the Company, that all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a
subsequent submission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Tests and Preclinical and Clinical Trials</U>. The preclinical studies and clinical trials conducted by or, to the Company&rsquo;s
knowledge, on behalf of the Company or any of its subsidiaries, that are described in the Registration Statement and the Prospectus, as
applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing,
are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws,
including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules&nbsp;and regulations promulgated thereunder and,
for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory
Practices and any applicable rules&nbsp;and regulations of the jurisdiction in which such trials and studies are being conducted; the
descriptions of the results of such studies and trials contained in the Registration Statement and the Prospectus are, to the Company&rsquo;s
knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to
the extent disclosed in the Registration Statement and the Prospectus, the Company and each of its subsidiaries, is not aware of any studies
or trials, the results of which the Company believes materially call into question the study or trial results described or referred to
in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical stage
of development; and, except to the extent disclosed in the Registration Statement or the Prospectus, the Company or any of its subsidiaries
have not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension
of any preclinical studies or clinical trials conducted by or on behalf of the Company or any of its subsidiaries, other than ordinary
course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications
have been made available to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Health Care Laws</U>. The Company and each of its subsidiaries are, and at all times have been, in compliance
with all applicable Health Care Laws and to the extent applicable to the Company&rsquo;s current business and product candidates, except
to the extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
For purposes of this Agreement, &ldquo;Health Care Laws&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act; the Public Health
Service Act (42 U.S.C. &sect;&sect; 201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state,
local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b));
(iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et
seq.); (iv)&nbsp;licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory
bodies; (v)&nbsp;all other applicable local, state, federal, national, supranational and foreign laws, relating to the regulation of the
Company&rsquo;s current business and product candidates; and (vi)&nbsp;the directives and regulations promulgated pursuant to such statutes
and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries, nor any of its respective officers, directors,
employees or, to the Company&rsquo;s knowledge, agents have engaged in activities which materially violate a Health Care Law. Neither
the Company nor any of its subsidiaries have received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product
operation or activity is in violation of any Health Care Laws nor, to the Company&rsquo;s knowledge, is any such claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually
or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries have filed, maintained or submitted all material
reports, documents, forms, notices, applications, records, submissions and supplements or amendments as required by any Health Care Laws,
and all such reports, documents, forms, notices, applications, records, submissions and supplements or amendments were complete and accurate
on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any
of its subsidiaries, nor any of its respective employees, officers, directors, or, to the Company&rsquo;s knowledge, agents is a party
to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed
by any governmental or regulatory authority. Additionally, neither the Company nor any of its subsidiaries, nor any of its respective
employees, officers, or directors, and, to the knowledge of the Company, its agents has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Undisclosed Relationships</U>. No relationship, direct or indirect, exists between or among the Company and its subsidiaries,
on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company, on the other, that
is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described
in such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Investment Company Act</U>. The Company is not and, after giving effect to the offering and sale of the Placement Shares and
the application of the proceeds thereof as described in the Registration Statement and the Prospectus, will not be required to register
as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning
of the Investment Company Act of 1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the
 &ldquo;<B><U>Investment Company Act</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Taxes</U>. The Company and its consolidated subsidiaries have paid all federal, state, local and foreign taxes and filed all
tax returns required to be paid or filed through the date hereof, except where the failure to file would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; and except as otherwise disclosed in each of the Registration Statement and
the Prospectus or as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there is no
tax deficiency that has been, or would reasonably be expected to be, asserted against the Company or any of its subsidiaries on any of
their properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Licenses
and Permits</U><I>.</I> The Company and each Subsidiary possess all licenses, certificates, permits and other authorizations issued by,
and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities
that are necessary for the ownership or lease of its properties or the conduct of its business as described in each of the Registration
Statement and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement and the Prospectus, neither
the Company nor any Subsidiary has received written notice of any revocation or modification of any such license, certificate, permit
or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary
course, except where such revocation, modification or non-renewal would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. To the Company&rsquo;s knowledge, no party granting any such licenses, certificates, permits and other
authorizations has taken any action to limit, suspend or revoke the same in any material respect. The Company and its subsidiaries have
filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent
submission) as required for maintenance of their licenses, certificates, permits and other authorizations that are necessary for the conduct
of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No Labor Disputes</U><I>.</I>
No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company,
is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees
of any of its principal suppliers, contractors or customers, except as would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Certain Environmental Matters</U>. (i)&nbsp;The Company and each of its subsidiaries (x)&nbsp;is in compliance with all, and
has not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions,
judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety,
the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &ldquo;<B><U>Environmental
Laws</U></B>&rdquo;); (y)&nbsp;has received and is in compliance with all, and has not violated any, permits, licenses, certificates or
other authorizations or approvals required of it under any Environmental Laws to conduct its business; and (z)&nbsp;has not received written
notice of any actual or potential liability under or relating to, or any actual or potential violation of, any Environmental Laws, including
for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no
costs or liabilities associated with Environmental Laws of or relating to the Company or any of its subsidiaries, except in the case of
each of (i)&nbsp;and (ii)&nbsp;above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Registration Statement and the Prospectus, (x)&nbsp;there
is no proceeding that is pending, or to the knowledge of the Company, that is contemplated, against the Company or any of its subsidiaries
under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably
believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and each of its subsidiaries is not aware of
any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning
hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect
and (z)&nbsp;the Company and its subsidiaries currently do not anticipate material capital expenditures relating to any Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>
<U>Hazardous Materials</U>. There has been no storage, generation, transportation, use, handling, treatment, Release (as defined below)
or, to the knowledge of the Company, threat of Release of Hazardous Materials (as defined below) by, relating to or caused by the Company
or any of its subsidiaries (or, to the knowledge of the Company, any other entity (including any predecessor) for whose acts or omissions
the Company is or could reasonably be expected to be liable) at, on, under or from any property or facility now or, to the knowledge of
the Company, previously owned, operated or leased by the Company or any of its subsidiaries, or, to the knowledge of the Company, at,
on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that
could reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &ldquo;<B><U>Hazardous Materials</U></B>&rdquo;
means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount,
including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing
materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any
Environmental Law. &ldquo;<B><U>Release</U></B>&rdquo; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging,
injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into
from or through any building or structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with ERISA</U>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee
Retirement Income Security Act of 1974, as amended (&ldquo;<B><U>ERISA</U></B>&rdquo;), for which the Company or any of its subsidiaries
or, to the Company&rsquo;s knowledge, any member of its &ldquo;<B><U>Controlled Group</U></B>&rdquo; (defined as any entity, whether or
not incorporated, that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity
that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m)&nbsp;or (o)&nbsp;of the Code would have
any liability (each, a &ldquo;<B><U>Plan</U></B>&rdquo;)) has been maintained in compliance with its terms and the requirements of any
applicable statutes, orders, rules&nbsp;and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction,
within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions
effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules&nbsp;of Section&nbsp;412
of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the
minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no
Plan is, or is reasonably expected to be, in &ldquo;at risk status&rdquo; (within the meaning of Section&nbsp;303(i)&nbsp;of ERISA) and
no Plan that is a &ldquo;multiemployer plan&rdquo; within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA is in &ldquo;endangered
status&rdquo; or &ldquo;critical status&rdquo; (within the meaning of Sections 304 and 305 of ERISA) (v)&nbsp;the fair market value of
the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used
to fund such Plan); (vi)&nbsp;no &ldquo;reportable event&rdquo; (within the meaning of Section&nbsp;4043(c)&nbsp;of ERISA and the regulations
promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of
the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification;
(viii)&nbsp;neither the Company nor any of its subsidiaries, nor any member of the Controlled Group has incurred, nor reasonably expects
to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation,
in the ordinary course and without default) in respect of a Plan (including a &ldquo;multiemployer plan&rdquo; within the meaning of Section&nbsp;4001(a)(3)&nbsp;of
ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the
aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal
year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&rsquo;s and its
Controlled Group affiliates&rsquo; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company&rsquo;s &ldquo;accumulated
post-retirement benefit obligations&rdquo; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount
of such obligations in the Company&rsquo;s most recently completed fiscal year, except in each case as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disclosure Controls</U>. The Company maintains an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies with the requirements of the Exchange Act applicable to the Company and
that has been designed to ensure that information required to be disclosed by the Company in reports that it will file or submit under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules&nbsp;and
forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&rsquo;s
management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out an evaluation of the effectiveness
of its disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Accounting Controls</U><I>.</I> The Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as
defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that comply with the applicable requirements of the Exchange Act and have been
designed by, or under the supervision of, its principal executive and principal financial officers, or persons performing similar functions,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company maintains internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets
is permitted only in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the
Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&rsquo;s
rules&nbsp;and guidelines applicable thereto. Based on the Company&rsquo;s most recent evaluation of its internal controls over financial
reporting pursuant to Rule&nbsp;13a-15(c)&nbsp;of the Exchange Act, there are no material weaknesses in the Company&rsquo;s internal controls.
The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (a)&nbsp;all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected
or are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and (b)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Insurance</U><I>. </I>The Company and its subsidiaries have insurance covering its properties, operations, personnel and business,
including business interruption insurance relating to physical damage to its facilities, which insurance is in amounts and insures against
such losses and risks as are, in the Company&rsquo;s reasonable judgement, adequate to protect the Company and its business; and the Company
and each of its subsidiaries (i)&nbsp;has not received written notice from any insurer or agent of such insurer that capital improvements
or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;does not have any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
at reasonable cost from similar insurers as may be necessary to continue its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Cybersecurity; Data Protection</U><I>. </I>(i)&nbsp;Except as would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect, the Company&rsquo;s and its subsidiaries&rsquo; information technology assets and equipment, including,
without limitation, those owned, licensed or otherwise used (excluding any public networks), such as its data communications lines, computers,
systems, networks, hardware, servers, software, websites, applications, and databases (collectively, &ldquo;<B><U>IT Systems</U></B>&rdquo;)
are adequate in capacity and operation for, and operate and perform in all material respects as required in connection with the operation
of the business of the Company as currently conducted as described in the Registration Statement and the Prospectus, to the Company&rsquo;s
knowledge, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; and (ii)&nbsp;the
Company and its subsidiaries have at all times in the past three (3)&nbsp;years implemented and maintained commercially reasonable controls,
policies, procedures, and safeguards to maintain and protect their material confidential information and the confidentiality, integrity,
availability, continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable, sensitive, confidential
or regulated data used in its business (&ldquo;<B><U>Company Data</U></B>&rdquo;), and (iii)&nbsp;to the knowledge of the Company, except
as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, there have been no breaches,
violations, outages, compromises, or unlawful or unauthorized acquisitions of, disclosures of, uses of or accesses to IT Systems and Company
Data, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to IT Systems and Company Data. The Company and each of its subsidiaries are presently
and, at all times, has been in compliance with all (i)&nbsp;applicable laws, statutes, judgments, orders, rules&nbsp;and regulations of
any court, arbitrator, governmental or regulatory authority; and (ii)&nbsp;internal policies and contractual obligations, each (i)&nbsp;and
(ii)&nbsp;relating to the privacy and security of IT Systems and Company Data and to the protection of such IT Systems and Company Data
from unauthorized use, access, misappropriation or modification, except to the extent that any non-compliance would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Unlawful Payments</U><I>.</I> Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the
Company nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company
or any Subsidiary has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating
to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, payment, promise to pay, or authorization or approval
of any direct or indirect unlawful payment or benefit or provision of anything of value, directly or indirectly, to any foreign or domestic
government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization,
or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or, as applicable, any law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or any other applicable anti-bribery or anti-corruption laws; or (iv)&nbsp;made, offered, agreed, requested or
taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence
payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintains and enforces,
and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery
and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Anti-Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted
at all times in compliance with applicable financial recordkeeping and reporting requirements, including the applicable money laundering
statutes of all jurisdictions where the Company and its subsidiaries conduct business, the rules&nbsp;or regulations thereunder and any
related or similar rules, regulations or guidelines applicable to such entities issued, administered or enforced by any governmental agency
(collectively, the &ldquo;<B><U>Anti-Money Laundering Laws</U></B>&rdquo;) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company and its subsidiaries with respect to the Anti-Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Conflicts with Sanctions Laws</U><I>. </I>Neither the Company nor any of its subsidiaries, nor its directors, officers, or
employees, nor, to the knowledge of the Company, any agent, affiliate or other person while acting on behalf of the Company or any of
its subsidiaries, is currently the subject or the target of any applicable sanctions administered or enforced by the U.S. government,
(including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B><U>OFAC</U></B>&rdquo;)
or the U.S. Department of State and including, without limitation, the designation as a &ldquo;specially designated national&rdquo; or
 &ldquo;blocked person&rdquo;), the United Nations Security Council (&ldquo;<B><U>UNSC</U></B>&rdquo;), the European Union, His Majesty&rsquo;s
Treasury (&ldquo;<B><U>HMT</U></B>&rdquo;) or other relevant sanctions authority (collectively, &ldquo;<B><U>Sanctions</U></B>&rdquo;),
nor is the Company located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without
limitation, the Crimea Region and the non-government controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine, the so called
Donetsk People&rsquo;s Republic, the so called Luhansk People&rsquo;s Republic, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B><U>Sanctioned
Country</U></B>&rdquo;); and the Company and its subsidiaries will not directly or indirectly use the proceeds of the offering of the
Placement Shares hereunder, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person
or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation,
is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country, or (iii)&nbsp;in
any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter,
advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in
and is not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or
was the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Broker&rsquo;s Fees</U><I>.</I> Neither the Company nor any of its subsidiaries are a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company for a brokerage commission,
finder&rsquo;s fee or like payment in connection with the offering and sale of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Registration Rights</U>. No person has the right to require the Company to register any securities for sale under the Securities
Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Placement Shares except
such rights as have been duly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Stabilization</U><I>.</I> The Company has not taken, directly or indirectly, any action designed to or that would reasonably
be expected to cause or result in any stabilization or manipulation of the price of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof
by the Company as described in each of the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of
Governors of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Forward-Looking Statements</U><I>.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities
Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement or the Prospectus
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xx)&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Statistical and Market Data</U><I>.</I> Nothing has come to the attention of the Company that has caused the Company to believe
that the statistical and market-related data included or incorporated in each of the Registration Statement and the Prospectus is not
based on or derived from sources that are reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Sarbanes-Oxley Act</U>. There is and has been no failure on the part of the Company, or to the Company&rsquo;s knowledge or any of
the Company&rsquo;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley
Act of 2002, as amended and the rules&nbsp;and regulations promulgated in connection therewith (the &ldquo;<B><U>Sarbanes-Oxley Act</U></B>&rdquo;),
including Section&nbsp;402 related to loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Status under the Securities Act</U>. The Company is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule&nbsp;405 under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Ratings</U>. There are no debt securities, convertible securities or preferred stock issued or guaranteed by the Company
that are rated by a &ldquo;nationally recognized statistical rating organization&rdquo;, as such term is defined in Section&nbsp;3(a)(62)
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bbb)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Distribution
of Offering Material by the Company</U>. The Company has not distributed and will not distribute, prior to the completion of BofA&rsquo;s
distribution of the Placement Shares, any offering material in connection with the offer and sale of the Placement Shares other than
the Prospectus or the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ccc)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exchange
Act Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or
hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act,
and, when read together with the other information in the Prospectus, at the Settlement Dates, will not contain an untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Reliance</U>. The Company has not relied upon BofA or legal counsel for BofA for any legal, tax or accounting advice in connection
with the offering and sale of the Placement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(eee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>XBRL</U>. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s
rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate signed by an officer of the Company
and delivered to BofA or to counsel for BofA pursuant to or in connection with this Agreement shall be deemed to be a representation
and warranty by the Company to BofA as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges that BofA and, for purposes
of the opinions to be delivered pursuant to <U>Section&nbsp;7</U> hereof, counsel to the Company and counsel to BofA, will rely upon
the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Covenants
of the Company</U>. The Company covenants and agrees with BofA that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares
is required to be delivered by BofA under the Securities Act (including in circumstances where such requirement may be satisfied pursuant
to Rule&nbsp;172 under the Securities Act), (i)&nbsp;the Company will notify BofA promptly of the time when any subsequent amendment
to the Registration Statement, other than documents incorporated by reference or amendments not related to the Placement Shares, has
been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus related to the Placement Shares
has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus related
to the Placement Shares or for additional information related to the Placement Shares, (ii)&nbsp;the Company will prepare and file with
the Commission, promptly upon BofA&rsquo;s reasonable request, any amendments or supplements to the Registration Statement or Prospectus
that, in BofA&rsquo;s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by
BofA (<I>provided, however</I>, that (A)&nbsp;the failure of BofA to make such request shall not relieve the Company of any obligation
or liability hereunder, or affect BofA&rsquo;s right to rely on the representations and warranties made by the Company in this Agreement,
(B)&nbsp;the Company has no obligation to provide BofA any advance copy of such filing or to provide BofA an opportunity to object to
such filing if the filing does not name BofA and does not relate to the transactions herein, and (C)&nbsp;the only remedy BofA shall
have with respect to the failure to make such filing (other than BofA&rsquo;s right under <U>Section&nbsp;9</U> hereof) will be to cease
making sales under this Agreement until such amendment or supplement is filed); (iii)&nbsp;the Company will not file any amendment or
supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Placement Shares
or a security convertible into the Placement Shares unless a copy thereof has been submitted to BofA within a reasonable period of time
before the filing and BofA has not reasonably objected thereto in writing within two business days (<I>provided, however</I>, that (A)&nbsp;the
failure of BofA to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect BofA&rsquo;s
right to rely on the representations and warranties made by the Company in this Agreement, (B)&nbsp;the Company has no obligation to
provide BofA any advance copy of such filing or to provide BofA an opportunity to object to such filing if the filing does not name BofA
and does not relate to the transaction herein, and (C)&nbsp;the only remedy BofA shall have with respect to the failure to provide BofA
with such copy or the filing of such amendment or supplement despite BofA&rsquo;s objection (other than BofA&rsquo;s rights under <U>Section&nbsp;9
</U>hereof) will be to cease making sales under this Agreement) and the Company will furnish to BofA at the time of filing thereof a
copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except
for those documents available via EDGAR; (iv)&nbsp;the Company will cause each amendment or supplement to the Prospectus, other than
documents incorporated by reference, to be filed with the Commission as required pursuant to the applicable paragraph of Rule&nbsp;424(b)&nbsp;of
the Securities Act, and (v)&nbsp;prior to the termination of this Agreement, the Company will notify BofA if at any time the Registration
Statement shall no longer be effective as a result of the passage of time pursuant to Rule&nbsp;415 under the Securities Act or otherwise.
Prior to the initial sale of any Placement Shares, the Company shall file a final Prospectus Supplement pursuant to Rule&nbsp;424(b)&nbsp;relating
to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notice
of Commission Stop Orders</U>. The Company will advise BofA, promptly after it receives notice or obtains knowledge thereof, of the issuance
or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension
of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding
for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain
its withdrawal if such a stop order should be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to the Placement Shares is required to be delivered
by BofA under the Securities Act with respect to a pending sale of the Placement Shares, (including in circumstances where such requirement
may be satisfied pursuant to Rule&nbsp;172 under the Securities Act), the Company will comply with all requirements imposed upon it by
the Securities Act, as from time to time in force, and to file on or before their respective due dates (taking into account any extensions
available under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company
with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d)&nbsp;or any other provision of or under the Exchange Act. If during
such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing,
not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with
the Securities Act, the Company will promptly notify BofA to suspend the offering of Placement Shares during such period and the Company
will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement
or omission or effect such compliance; <I>provided, however</I>, that the Company may delay the filing of any amendment or supplement
if, in the judgment of the Company, it is in the best interest of the Company to do so, <I>provided, further</I>, that no Placement Notice
is in effect during such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Listing
of Placement Shares</U>. During any period in which the Prospectus relating to the Placement Shares is required to be delivered by BofA
under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may
be satisfied pursuant to Rule&nbsp;172 under the Securities Act), the Company will use its commercially reasonable efforts to cause the
Placement Shares to be listed on Nasdaq and to qualify the Placement Shares for sale under the securities laws of such jurisdictions
as BofA reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Placement
Shares; <I>provided, however,</I> that the Company shall not be required in connection therewith to qualify as a foreign corporation
or dealer in securities or file a general consent to service of process in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Delivery
of Registration Statement and Prospectus</U>. The Company will furnish to BofA and its counsel (at the expense of the Company) copies
of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements
to the Registration Statement or Prospectus that are filed with the Commission during any period in which a Prospectus relating to the
Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission during such
period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities
as BofA may from time to time reasonably request; <I>provided, however,</I> that the Company shall not be required to furnish any document
(other than the Prospectus) to BofA to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Earnings
Statement</U>. The Company will make generally available to its security holders as soon as practicable an earnings statement that satisfies
the provisions of Section&nbsp;11(a)&nbsp;and Rule&nbsp;158 of the Securities Act; <I>provided</I> that the Company will be deemed to
have furnished such statements to its security holders to the extent they are filed via EDGAR. For the avoidance of doubt, the Company&rsquo;s
timely compliance with the reporting requirements of the Exchange Act shall be deemed to satisfy this <U>Section&nbsp;7(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Expenses</U>.
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, in accordance with
the provisions of <U>Section&nbsp;11</U> hereunder, will pay the following expenses all incident to the performance of its obligations
hereunder, including, but not limited to, expenses relating to (i)&nbsp;the preparation, printing and filing of the Registration Statement
and each amendment and supplement thereto, of each Prospectus and of each amendment and supplement thereto, (ii)&nbsp;the preparation,
issuance and delivery of the Placement Shares, (iii)&nbsp;the qualification of the Placement Shares under securities laws in accordance
with the provisions of <U>Section&nbsp;7(d)</U>&nbsp;of this Agreement, including filing fees (provided, however, that any fees or disbursements
of counsel for BofA in connection therewith shall be paid by BofA except as set forth in (vii)&nbsp;below), (iv)&nbsp;the printing and
delivery to BofA of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v)&nbsp;the fees and
expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi)&nbsp;the filing
fees and expenses, if any, of the Commission, (vii)&nbsp;the filing fees and associated legal expenses of BofA&rsquo;s outside counsel
for filings with the FINRA Corporate Financing Department, such legal expense reimbursement not to exceed $10,000 and, (viii)&nbsp;the
reasonable fees and disbursements of BofA&rsquo;s counsel in an amount not to exceed $75,000 in connection with the execution of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Other Sales</U>. During the pendency of any Placement Notice given hereunder, and for two (2)&nbsp;trading days following the termination
of any Placement Notice given hereunder, the Company shall provide BofA notice as promptly as reasonably practicable before it offers
to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than Placement
Shares offered pursuant to the provisions of this Agreement) or securities convertible into or exchangeable for Common Stock, warrants
or any rights to purchase or acquire Common Stock; <I>provided</I>, that such notice shall not be required in connection with (i)&nbsp;the
offer, issuance, grant or sale of Common Stock (including restricted Common Stock), options to purchase shares of Common Stock or Common
Stock, restricted stock units or other equity awards issuable upon the exercise of options or other equity awards pursuant to any equity
incentive, stock option, stock bonus, employee stock purchase, or other compensatory or stock plan or arrangement described in the Prospectus,
(ii)&nbsp;the offer or issuance of securities in connection with an acquisition, merger or sale or purchase of assets, (iii)&nbsp;the
issuance or sale of Common Stock pursuant to any dividend reinvestment plan that the Company may adopt, in its sole discretion, from
time to time provided the implementation of such plan is disclosed to BofA in advance, (iv)&nbsp;the issuance of any shares of Common
Stock issuable upon the exchange, conversion or redemption of securities or the exercise of warrants, options or other rights in effect
or outstanding, or (v)&nbsp;the issuance of any shares of Common Stock, or securities convertible into or exercisable for Common Stock,
offered and sold in a privately negotiated transaction to vendors, customers, investors, strategic partners or potential strategic partners,
licensors, and otherwise conducted in a manner so as not to be integrated with the offering of the Placement Shares contemplated hereby;
provided, however, that the aggregate number of Common Stock, or securities convertible into or exercisable or exchangeable for Common
Stock, that the Company may issue or agree to issue pursuant to this clause (v)&nbsp;shall not exceed 10.0% of the total outstanding
Common Stock immediately following such issuance. Notwithstanding the foregoing provisions, nothing herein shall be construed to restrict
the Company&rsquo;s ability to file, or require the Company to provide notice BofA of the filing of, a registration statement under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Change
of Circumstances</U>. The Company will, during the pendency of a Placement Notice, advise BofA promptly after it shall have received
notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate,
letter or other document provided to BofA pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Due
Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by BofA or its agents in connection
with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior
corporate officers, during regular business hours and at the Company&rsquo;s principal offices, as BofA may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Required
Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act shall require, the
Company will (i)&nbsp;file a prospectus supplement with the Commission under the applicable paragraph of Rule&nbsp;424(b)&nbsp;under
the Securities Act, and (ii)&nbsp;deliver such number of copies of each such prospectus supplement to each exchange or market on which
such sales were effected as may be required by the rules&nbsp;or regulations of such exchange or market. The Company shall disclose in
its quarterly reports on Form&nbsp;10-Q and in its annual report on Form&nbsp;10-K, the number of the Placement Shares sold through BofA
under this Agreement, and the gross proceeds and Net Proceeds to the Company from the sale of the Placement Shares and the compensation
paid by the Company with respect to sales of the Placement Shares pursuant to this Agreement during the relevant quarter or, in the case
of an Annual Report on Form&nbsp;10-K, during the fiscal year covered by such Annual Report and the fourth quarter of such fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bring-Down
Dates; Certificate</U>. On or prior to the First Delivery Date, and each time thereafter during the term of this Agreement, (i)&nbsp;the
Company files the Prospectus relating to the Placement Shares or amends or supplements the Registration Statement or the Prospectus relating
to the Placement Shares (other than a prospectus supplement filed in accordance with <U>Section&nbsp;7(l)</U>&nbsp;of this Agreement)
by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of document(s)&nbsp;by reference to
the Registration Statement or the Prospectus relating to the Placement Shares; (ii)&nbsp;the Company files an annual report on Form&nbsp;10-K
under the Exchange Act; (iii)&nbsp;the Company files its quarterly reports on Form&nbsp;10-Q under the Exchange Act; (iv)&nbsp;the Company
files a report on Form&nbsp;8-K containing amended financial information (other than an earnings release or other information &ldquo;furnished&rdquo;
under Items 2.02, 7.01. or 9.01 of Form&nbsp;8-K) under the Exchange Act; or (v)&nbsp;as BofA may reasonably request (each date of filing
of one or more of the documents referred to in clauses (i)&nbsp;through (v)&nbsp;shall be a &ldquo;<B><U>Bring-Down Date</U></B>&rdquo;);
the Company shall furnish BofA (but in the case of clause (iv)&nbsp;above only if (1)&nbsp;a Placement Notice is pending, (2)&nbsp;BofA
reasonably determines that the information contained in such Form&nbsp;8-K is material to a holder of Common Stock, and (3)&nbsp;BofA
requests such certification within three (3)&nbsp;days after the filing of such Form&nbsp;8-K with the Commission) with a certificate,
in the form attached hereto as <U>Exhibit&nbsp;7(m)</U>&nbsp;within three (3)&nbsp;Trading Days of any Bring-Down Date if requested by
BofA. The requirement to provide a certificate under this <U>Section&nbsp;7(m)</U>&nbsp;shall be automatically waived for any Bring-Down
Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date
the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Bring-Down Date) and the next
occurring Bring-Down Date; <I>provided</I>, <I>however</I>, that such waiver shall not apply for any Bring-Down Date on which the Company
files its annual report on Form&nbsp;10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares
following a Bring-Down Date when the Company relied on such waiver and did not provide BofA with a certificate under this <U>Section&nbsp;7(m)</U>,
then before the Company delivers the Placement Notice or BofA sells any Placement Shares, the Company shall provide BofA with a certificate,
in the form attached hereto as <U>Exhibit&nbsp;7(m)</U>, dated the date of the Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Legal
Opinion</U>. On or prior to the First Delivery Date and within three (3)&nbsp;Trading Days of each Bring-Down Date with respect to which
the Company is obligated to deliver a certificate in the form attached hereto as <U>Exhibit&nbsp;7(m)</U>&nbsp;for which no waiver is
applicable, the Company shall cause to be furnished to BofA: (i)&nbsp;a written opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati,
P.C.(&ldquo;<B><U>Company Counsel</U></B>&rdquo;), or other counsel satisfactory to BofA and (ii)&nbsp;a written opinion of Wilson Sonsini
Goodrich&nbsp;&amp; Rosati, P.C., intellectual property counsel of the Company (&ldquo;Intellectual Property Counsel&rdquo;), each in
form and substance satisfactory to BofA and its counsel, dated the date that the opinion is required to be delivered, modified, as necessary,
to relate to the Registration Statement and the Prospectus as then amended or supplemented; <I>provided</I>, <I>however</I>, that in
lieu of such opinions for subsequent Bring-Down Dates, Company Counsel may furnish BofA with a letter (a &ldquo;<B><U>Reliance Letter</U></B>&rdquo;)
to the effect that BofA may rely on a prior opinion delivered under this <U>Section&nbsp;7(n)</U>&nbsp;to the same extent as if it were
dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and
the Prospectus as amended or supplemented at such Bring-Down Date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Comfort
Letter</U>. On or prior to the First Delivery Date and within three (3)&nbsp;Trading Days of each Bring-Down Date with respect to which
the Company is obligated to deliver a certificate in the form attached hereto as <U>Exhibit&nbsp;7(m)</U>&nbsp;for which no waiver is
applicable, the Company shall cause its independent accountants to furnish BofA a letter (the &ldquo;<B><U>Comfort Letter</U></B>&rdquo;),
dated the date the Comfort Letter is delivered, in form and substance satisfactory to BofA, (i)&nbsp;confirming that they are an independent
registered public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board, (ii)&nbsp;stating,
as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered
by accountants&rsquo; &ldquo;comfort letters&rdquo; to BofA in connection with registered public offerings (the first such letter, the
 &ldquo;<B><U>Initial Comfort Letter</U></B>&rdquo;) and (iii)&nbsp;updating the Initial Comfort Letter with any information that would
have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration
Statement and the Prospectus, as amended and supplemented to the date of such letter; <I>provided</I> that the Company shall be required
to furnish to BofA no more than one Comfort Letter hereunder per each filing of an annual report on Form&nbsp;10-K or a quarterly report
on Form&nbsp;10-Q.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Market
Activities</U>. The Company will not, directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Placement Shares or (ii)&nbsp;sell, bid for, or purchase the Placement Shares to be issued and sold pursuant
to this Agreement in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other
than BofA; provided, however, that the Company may bid for and purchase shares of its common stock in accordance with Rule&nbsp;10b-18
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and its subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable
and customary for the business for which it is engaged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. The Company and each of its subsidiaries shall use their commercially reasonable efforts to maintain, or cause to be maintained,
all applicable material environmental permits, licenses and other authorizations required by applicable federal, state and local law
in order to conduct their businesses as described in the Prospectus, and the Company and each of its subsidiaries shall conduct their
businesses, or cause their businesses to be conducted, in substantial compliance with such permits, licenses and authorizations and with
applicable Environmental Laws, except where the failure to maintain or be in compliance with such permits, licenses and authorizations
could not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor its subsidiaries
will be or become, at any time prior to the termination of this Agreement, an &ldquo;investment company,&rdquo; as such term is defined
in the Investment Company Act, assuming no change in the Commission&rsquo;s current interpretation as to entities that are not considered
an investment company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Securities
Act and Exchange Act</U>. The Company will use its commercially reasonable efforts to comply with all requirements imposed upon it by
the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the continuance of sales of, or
dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Offer to Sell</U>. Other than a Permitted Free Writing Prospectus, neither BofA nor the Company (including its agents and representatives,
other than BofA in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined
in Rule&nbsp;405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation
of an offer to buy Placement Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley
Act</U>. The Company and its subsidiaries will use their commercially reasonable efforts to comply with all effective applicable provisions
of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Affirmation</U>.
Each Placement Notice delivered by the Company to BofA shall be deemed to be (i)&nbsp;an affirmation that the representations, warranties
and agreements of the Company herein contained and contained in any certificate delivered to BofA pursuant hereto are true and correct
at the time of delivery of such Placement Notice, and (ii)&nbsp;an undertaking that such representations, warranties and agreements will
be true and correct on any applicable Time of Sale and Settlement Date, as though made at and as of each such time (it being understood
that such representations, warranties and agreements shall relate to the Registration Statement and the Prospectus as amended and supplemented
to the time of such Placement Notice acceptance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Renewal</U>.
If immediately prior to the third anniversary (the &ldquo;<B><U>Renewal Deadline</U></B>&rdquo;) of the initial effective date of the
Registration Statement, the aggregate gross sales price of Placement Shares sold by the Company is less than the Maximum Amount and this
Agreement has not expired or been terminated, the Company will, prior to the Renewal Deadline, file, if it has not already done so and
is eligible to do so, a new shelf registration statement relating to the Placement Shares, in a form satisfactory to BofA, and, if not
automatically effective, will use its best efforts to cause such registration statement to be declared effective within 60 days after
the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Placement
Shares to continue as contemplated in the expired registration statement relating to the Placement Shares. References herein to the Registration
Statement shall include such new shelf registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
to BofA&rsquo;s Obligations</U>. The obligations of BofA hereunder with respect to a Placement Notice will be subject to the continuing
accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of
its obligations hereunder and thereunder, to the completion by BofA of a due diligence review satisfactory to BofA in its reasonable
judgment, and to the continuing satisfaction (or waiver by BofA in its sole discretion) of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration
Statement Effective</U>. The Registration Statement shall be effective and shall be available for (i)&nbsp;all sales of Placement Shares
issued pursuant to all prior Placement Notices and (ii)&nbsp;the sale of all Placement Shares contemplated to be issued pursuant to any
Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Material Notices</U>. None of the following events shall have occurred and be continuing: (i)&nbsp;receipt by the Company or any of its
subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during
the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that
purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such
purpose; or (iv)&nbsp;the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus
or any material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires
the making of any changes in the Registration Statement, related Prospectus or such documents so that, in the case of the Registration
Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Misstatement or Material Omission</U>. BofA shall not have advised the Company that the Registration Statement or Prospectus, or any
amendment or supplement thereto, contains an untrue statement of fact that in BofA&rsquo;s reasonable opinion is material, or omits to
state a fact that in BofA&rsquo;s opinion is material and is required to be stated therein or is necessary to make the statements therein
not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Material
Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the Commission, there shall
not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any material adverse
change or any development that could reasonably be expected to result in a Material Adverse Effect, or any downgrading in or withdrawal
of the rating assigned to any of the Company&rsquo;s securities (other than asset backed securities) by any rating organization or a
public announcement by any rating organization that it has under surveillance or review its rating of any of the Company&rsquo;s securities
(other than asset backed securities), the effect of which, in the case of any such action by a rating organization described above, in
the reasonable judgment of BofA (without relieving the Company of any obligation or liability it may otherwise have), is so material
as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated
in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Counsel Legal Opinion</U>. BofA shall have received the opinions of Company Counsel and Intellectual Property Counsel required to be
delivered pursuant to <U>Section&nbsp;7(n)</U>&nbsp;on or before the date on which such delivery of such opinion is required pursuant
to <U>Section&nbsp;7(n)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>BofA
Counsel Legal Opinion</U>. BofA shall have received from Cooley LLP, counsel for BofA, such opinion or opinions, on or before the date
on which the delivery of the Company Counsel legal opinion is required pursuant to <U>Section&nbsp;7(n)</U>, with respect to such matters
as BofA may reasonably require, and the Company shall have furnished to such counsel such documents as they reasonably request for enabling
them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Comfort
Letter</U>. BofA shall have received the Comfort Letter required to be delivered pursuant to <U>Section&nbsp;7(o)</U>&nbsp;on or before
the date on which such delivery of such Comfort Letter is required pursuant to <U>Section&nbsp;7(o)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Officer&rsquo;s
Certificate</U>. BofA shall have received the certificate required to be delivered pursuant to <U>Section&nbsp;7(m)</U>&nbsp;on or before
the date on which delivery of such certificate is required pursuant to <U>Section&nbsp;7(m)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Secretary&rsquo;s
Certificate</U>. On or prior to the First Delivery Date, BofA shall have received a certificate, signed on behalf of the Company by its
corporate secretary, in form and substance reasonably satisfactory to BofA and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Suspension</U>. Trading in the Common Stock shall not have been suspended on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Other
Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to <U>Section&nbsp;7(m)</U>, the Company
shall have furnished to BofA such appropriate further information, certificates and documents as BofA may have reasonably requested.
All such opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof. The Company will
furnish BofA with such conformed copies of such opinions, certificates, letters and other documents as BofA shall have reasonably requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Securities
Act Filings Made</U>. All filings with the Commission required by Rule&nbsp;424 under the Securities Act to have been filed prior to
the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule&nbsp;424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Approval
for Listing</U>. To the extent required by the rules&nbsp;of Nasdaq, the Placement Shares shall either have been (i)&nbsp;approved for
listing on Nasdaq, subject only to notice of issuance, or (ii)&nbsp;the Company shall have filed an application for listing of the Placement
Shares on Nasdaq at, or prior to, the issuance of any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Termination Event</U>. There shall not have occurred any event that would permit BofA to terminate this Agreement pursuant to <U>Section&nbsp;11(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Company
Indemnification</U>. The Company agrees to indemnify and hold harmless BofA, its respective affiliates (as such term is defined in Rule&nbsp;501(b)&nbsp;of
the 1933 Act Regulations), the directors, officers, partners, employees and agents of BofA and each person, if any, who (i)&nbsp;controls
BofA within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, or (ii)&nbsp;is controlled by
or is under common control with BofA from and against any and all losses, claims, liabilities, reasonable and documented expenses and
damages (including, but not limited to, any and all reasonable and documented investigative, legal and other expenses incurred in connection
with, and any and all amounts paid in settlement (in accordance with <U>Section&nbsp;9(c)</U>) of, any action, suit or proceeding between
any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party, or otherwise, or any
claim asserted), within 30 days of the written receipt of the documented expenses by the indemnifying party, to which BofA, or any such
person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common
law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly,
on (x)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus
or any amendment or supplement to the Registration Statement or the Prospectus or in any free writing prospectus or in any application
or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed
in any jurisdiction in order to qualify the Common Stock under the securities laws thereof or filed with the Commission, or (y)&nbsp;the
omission or alleged omission to state in any such document a material fact required to be stated in it or necessary to make the statements
in it not misleading; <I>provided</I>, <I>however</I>, that this indemnity agreement shall not apply to the extent that such loss, claim,
liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused directly or indirectly
by an untrue statement or omission made in reliance upon and in conformity with solely Agent&rsquo;s Information. &ldquo;<B>Agent&rsquo;s
Information</B>&rdquo; means, solely, the following information in the Prospectus: the second sentence of the fourth paragraph and the
twelfth paragraph under the caption &ldquo;Plan of Distribution&rdquo; in the Prospectus. This indemnity agreement will be in addition
to any liability that the Company might otherwise have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>BofA
Indemnification</U>. BofA agrees to indemnify and hold harmless the Company, its affiliates (as such term is defined in Rule&nbsp;501(b)&nbsp;of
the 1933 Act Regulations), its directors and each officer of the Company that signed the Registration Statement, and each person, if
any, who (i)&nbsp;controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange
Act or (ii)&nbsp;is controlled by or is under common control with the Company against any and all loss, liability, claim, reasonable
and documented damage and expense described in the indemnity contained in <U>Section&nbsp;9(a)</U>, as incurred, but only with respect
to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto)
or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent&rsquo;s Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Procedure</U>.
Any party that proposes to assert the right to be indemnified under this <U>Section&nbsp;9</U> will, promptly after receipt of notice
in writing of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or
parties under this <U>Section&nbsp;9</U>, notify each such indemnifying party in writing of the commencement of such action, enclosing
a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i)&nbsp;any
liability that it might have to any indemnified party otherwise than under this <U>Section&nbsp;9</U> and (ii)&nbsp;any liability that
it may have to any indemnified party under the foregoing provision of this <U>Section&nbsp;9</U> unless, and only to the extent that,
such omission results in the forfeiture or material impairment of substantive rights or defenses by the indemnifying party. If any such
action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will
be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after
receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified,
to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying
party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party
for any legal or other expenses except as provided below and except for the reasonable and documented costs of investigation subsequently
incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel
in any such action, but the reasonable and documented fees, expenses and other charges of such counsel will be at the expense of such
indemnified party unless (1)&nbsp;the employment of counsel by the indemnified party has been authorized in writing by the indemnifying
party, (2)&nbsp;the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available
to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3)&nbsp;a conflict
or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying
party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified
party) or (4)&nbsp;the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable time
after receiving notice of the commencement of the action, in each of which cases the reasonable and documented fees, disbursements and
other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or
parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees,
disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all such
indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party within 30 days
of the written receipt of the documented expenses by the indemnifying party. An indemnifying party will not, in any event, be liable
for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written
consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action
or proceeding relating to the matters contemplated by this <U>Section&nbsp;9</U> (whether or not any indemnified party is a party thereto),
unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising
or that may arise out of such claim, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Contribution</U>.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of this <U>Section&nbsp;9</U> is applicable in accordance with its terms but for any reason is held to be unavailable from the Company
or BofA, the Company and BofA will contribute to the total losses, claims, liabilities, reasonable and documented expenses and damages
(including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of,
any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other
than BofA, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration
Statement and directors of the Company, who also may be liable for contribution) to which the Company and BofA may be subject in such
proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and BofA on the other. The
relative benefits received by the Company on the one hand and BofA on the other hand shall be deemed to be in the same proportion as
the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation
received by BofA from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing
sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect
not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and
BofA, on the other, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action
in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by the Company or BofA, the intent of the parties and their relative
knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and BofA agree that it
would not be just and equitable if contributions pursuant to this <U>Section&nbsp;9(d)</U>&nbsp;were to be determined by pro rata allocation
or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid
or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred
to above in this <U>Section&nbsp;9(d)</U>&nbsp;shall be deemed to include, for the purpose of this <U>Section&nbsp;9(d)</U>, any documented
legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or
claim to the extent consistent with <U>Section&nbsp;9(c)</U>&nbsp;hereof. Notwithstanding the foregoing provisions of this <U>Section&nbsp;9(d)</U>,
BofA shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section&nbsp;9(d)</U>, any person who
controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents
of BofA, will have the same rights to contribution as that party, and each officer of the Company who signed the Registration Statement
and each director of the Company will have the same rights to contribution as the Company, subject in each case to the provisions hereof.
Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which
a claim for contribution may be made under this <U>Section&nbsp;9(d)</U>, will notify any such party or parties from whom contribution
may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other
obligation it or they may have under this <U>Section&nbsp;9(d)</U>&nbsp;except to the extent that the failure to so notify such other
party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement
entered into pursuant to the last sentence of <U>Section&nbsp;9(c)</U>&nbsp;hereof, no party will be liable for contribution with respect
to any action or claim settled without its written consent if such consent is required pursuant to <U>Section&nbsp;9(c)</U>&nbsp;hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Representations
and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in <U>Section&nbsp;9</U> of this Agreement
and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their
respective dates, regardless of (i)&nbsp;any investigation made by or on behalf of BofA, any controlling persons, or the Company (or
any of their respective officers, directors or controlling persons), (ii)&nbsp;delivery and acceptance of the Placement Shares and payment
therefor or (iii)&nbsp;any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">BofA
shall have the right by giving written notice as hereinafter specified at any time to terminate this Agreement if (i)&nbsp;any
Material Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect has occurred
that, in the reasonable judgment of BofA, may materially impair the ability of BofA to sell the Placement Shares hereunder;
(ii)&nbsp;the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder, <I>provided,
however</I>, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion,
or letter required under <U>Sections 7(m)</U>, <U>7(n)</U>, or <U>7(o)</U>, BofA&rsquo;s right to terminate shall not arise unless
such failure to deliver (or cause to be delivered) continues for more than thirty (30) days from the date such delivery was
required; (iii)&nbsp;any other condition of BofA&rsquo;s obligations hereunder is not fulfilled; or (iv)&nbsp;any suspension or
limitation of trading in the Placement Shares or in securities generally on Nasdaq shall have occurred. Any such termination shall
be without liability of any party to any other party except that the provisions of <U>Section&nbsp;7(g)</U>&nbsp;(Expenses), <U>Section&nbsp;9</U>
(Indemnification and Contribution), <U>Section&nbsp;10 </U>(Representations and Agreements to Survive Delivery), <U>Section&nbsp;16</U>
(Applicable Law; Consent to Jurisdiction) and <U>Section&nbsp;17</U> (Waiver of Jury Trial) hereof shall remain in full force and
effect notwithstanding such termination. If BofA elects to terminate this Agreement as provided in this <U>Section&nbsp;11(a)</U>,
BofA shall provide the required notice as specified in <U>Section&nbsp;12</U> (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company shall have the right, by giving ten (10)&nbsp;days&rsquo; notice as hereinafter specified to terminate this Agreement in its
sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other
party except that the provisions of <U>Section&nbsp;7(g)</U>, <U>Section&nbsp;9</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;16</U> and
<U>Section&nbsp;17</U> hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">BofA
shall have the right, by giving ten (10)&nbsp;days&rsquo; notice as hereinafter specified to terminate this Agreement in its sole discretion
at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except
that the provisions of <U>Section&nbsp;7(g)</U>, <U>Section&nbsp;9</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;16</U> and <U>Section&nbsp;17
</U>hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Unless
earlier terminated pursuant to this <U>Section&nbsp;11</U>, this Agreement shall automatically terminate upon the issuance and sale of
all of the Placement Shares through BofA on the terms and subject to the conditions set forth herein; <I>provided</I> that the provisions
of <U>Section&nbsp;7(g)</U>, <U>Section&nbsp;9</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;16</U> and <U>Section&nbsp;17</U> hereof
shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Agreement shall remain in full force and effect unless terminated pursuant to <U>Sections 11(a)</U>, <U>(b)</U>, <U>(c)</U>, or <U>(d)</U>&nbsp;above
or otherwise by mutual agreement of the parties; <I>provided, however, </I>that any such termination by mutual agreement shall in
all cases be deemed to provide that <U>Section&nbsp;7(g)</U>, <U>Section&nbsp;9</U>, <U>Section&nbsp;10</U>, <U>Section&nbsp;16</U>
and <U>Section&nbsp;17</U> shall remain in full force and effect. Upon termination of this Agreement, subject to <U>Section&nbsp;11(f)</U>,
the Company shall not have any liability to BofA for any discount, commission or other compensation with respect to any Placement
Shares not otherwise sold by BofA under this Agreement, or otherwise, except with respect to reimbursement of expenses pursuant to <U>Section&nbsp;7(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided, however,</I> that
such termination shall not be effective until the close of business on the date of receipt of such notice by BofA or the Company, as
the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares
shall settle in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement
shall be in writing, unless otherwise specified in this Agreement, and if sent to BofA, shall be delivered to BofA at BofA Securities,&nbsp;Inc.,
One Bryant Park, New York, NY 10036, Attention: ATM Execution (email: dg.atm_execution@bofa.com) and ECM Legal (email: dg.ecm_legal@bofa.com),
with a copy to Cooley LLP, 55 Hudson Yards, New York, NY 10001, Attention: Daniel I. Goldberg, email: dgoldberg@cooley.com; or if sent
to the Company, shall be delivered to Edgewise Therapeutics,&nbsp;Inc., 3145 Colorado Ave., Boulder, CO 80303, attention: John Moore,
email: jmoore@edgewisetx.com, with a copy to Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., 650 Page&nbsp;Mill Road, Palo Alto, CA
94304, attention: Jennifer Knapp, email: jknapp@wsgr.com. Each party to this Agreement may change such address for notices by sending
to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed
given (i)&nbsp;when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m.,
New York City time, on a Business Day (as defined below), or, if such day is not a Business Day on the next succeeding Business Day,
(ii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii)&nbsp;on the Business
Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes
of this Agreement, &ldquo;<B><U>Business Day</U></B>&rdquo; shall mean any day on which the Nasdaq and commercial banks in the City of
New York are open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and BofA and their respective successors
and the affiliates, controlling persons, officers and directors referred to in <U>Section&nbsp;9</U> hereof. References to any of the
parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; <I>provided</I>,
<I>however</I>, that BofA may assign its rights and obligations hereunder to an affiliate of BofA without obtaining the Company&rsquo;s
consent, so long as such affiliate is a registered broker-dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Adjustments
for Share Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted
to take into account any share split, share dividend or similar event effected with respect to the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement; Amendment; Severability</U>. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued
pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both
written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be
amended except pursuant to a written instrument executed by the Company and BofA. In the event that any one or more of the provisions
contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of
competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal
and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable
term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms
and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Applicable
Law; Consent to Jurisdiction</U>. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State
of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably submits to the non-exclusive jurisdiction
of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder
or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified
or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Waiver
of Jury Trial</U>. The Company and BofA each hereby irrevocably waives any right it may have to a trial by jury in respect of any claim
based upon or arising out of this Agreement or any transaction contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Absence
of Fiduciary Relationship</U><I>. </I>The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">BofA
has been retained solely to act as an arm&rsquo;s length contractual counterparty to the Company in connection with the sale of the Placement
Shares contemplated hereby and that no fiduciary, advisory or agency relationship between the Company and BofA has been created in respect
of any of the transactions contemplated by this Agreement, irrespective of whether BofA has advised or is advising the Company on other
matters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company has been advised that BofA and its affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and that BofA has no obligation to disclose such interests and transactions to the Company by virtue of any
fiduciary, advisory or agency relationship; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Company waives, to the fullest extent permitted by law, any claims it may have against BofA, for breach of fiduciary duty or alleged
breach of fiduciary duty in connection with this Agreement and agrees that BofA shall have no liability (whether direct or indirect)
to the Company in respect of such a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the
Company, including stockholders, partners, employees or creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or by electronic
transmission of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Remainder of Page&nbsp;Intentionally Blank]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth the understanding between the Company and BofA, please so indicate in the space provided below for that purpose, whereupon
this letter shall constitute a binding agreement between the Company and BofA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BOFA SECURITIES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Aamir Mecklai</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:&#8239;Aamir Mecklai</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&#8239;</FONT>Managing Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ACCEPTED as of the date&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">first-above written:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EDGEWISE THERAPEUTICS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Kevin Koch</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Kevin Koch, Ph.D.&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive
    Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature Page to the
Sales Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><U>form
</U></B></FONT><B><U><FONT STYLE="text-transform: uppercase">of PLACEMENT NOTICE</FONT></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.8in">From:</TD><TD>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Cc:</TD><TD>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">To:</TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.8in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BofA
                                            At the Market Offering&mdash;Placement Notice</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the terms and subject to the conditions contained in the </FONT>Sales Agreement between Edgewise Therapeutics,&nbsp;Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and BofA and Company, LLC (&ldquo;<U>BofA</U>&rdquo;) dated June&nbsp;16, 2023
(the &ldquo;<U>Agreement</U>&rdquo;),&nbsp;I hereby request on behalf of the Company that BofA sell up to [ ] shares of the Company&rsquo;s
common stock, par value $0.0001 per share, at a minimum market price of $_______ per share. Sales should begin on the date of this Notice
and shall continue until [DATE] [all shares are sold].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Notice Parties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><U>Company</U></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Kevin Koch, Ph.D.</FONT></TD>
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">President and Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">R. Michael Carruthers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><U>BofA</U></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Greg Butz</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Managing Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BofA shall be paid compensation of up to 3.0%
of the gross proceeds from the sales of Common Stock pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit&nbsp;7(m)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>OFFICER&rsquo;S CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned, the duly qualified and elected Chief Financial Officer of Edgewise Therapeutics,&nbsp;Inc., a Delaware corporation (&ldquo;<B><U>Company</U></B>&rdquo;),
does hereby certify in such capacity and on behalf of the Company, pursuant to <U>Section&nbsp;7(m)</U>&nbsp;of the Sales Agreement dated
June&nbsp;16</FONT>, 2023 (the &ldquo;<B><U>Sales Agreement</U></B>&rdquo;) between the Company and BofA and Company, LLC, that
to the best of the knowledge of the undersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
representations and warranties of the Company in <U>Section&nbsp;6</U> of the Sales Agreement (A)&nbsp;to the extent such representations
and warranties are subject to qualifications and exceptions contained therein relating to materiality or a Material Adverse Effect, are
true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except
for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date, and
(B)&nbsp;to the extent such representations and warranties are not subject to any qualifications or exceptions, are true and correct
in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly
made on and as of the date hereof except for those representations and warranties that speak solely as of a specific date and which were
true and correct as of such date; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales
Agreement at or prior to the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in the Registration Statement and Prospectus, including all documents incorporated by reference therein, since
the filing of the Company&rsquo;s annual report on Form 10-K for the year ended December 31, 2022, there have been no material changes with
respect to the Company's Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cooley LLP and Wilson Sonsini
Goodrich&nbsp;&amp; Rosati, P.C. are entitled to rely upon this Certificate in connection with the opinions given by such firms pursuant
to the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms used but
not defined herein shall have the meanings ascribed to them in the Sales Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">EDGEWISE THERAPEUTICS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: R. Michael Carruthers&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2318809d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%; font-size: 10pt"><IMG SRC="tm2318809d2_ex5-1img001.jpg" ALT=""></TD>
    <TD STYLE="width: 46%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 97.05pt">Wilson Sonsini Goodrich&nbsp;&amp;
    Rosati<BR>
    Professional Corporation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 97.05pt">1881 9th Street<BR>
    Suite&nbsp;110<BR>
    Boulder, CO 80302</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 97.05pt"><FONT STYLE="font-variant: small-caps">o</FONT>:
    303.256.5900<BR>
    <FONT STYLE="font-variant: small-caps">f</FONT>: 866.974.7329</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June&nbsp;16, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edgewise Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1715 38th St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boulder, Colorado 80301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Re: Registration Statement on Form&nbsp;S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to Edgewise Therapeutics,&nbsp;Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), in connection with the registration of the offer and sale of up to $125,000,000 of shares (the
 &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, $0.0001 par value per share, pursuant to the Company&rsquo;s shelf registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-264083) filed on April&nbsp;1, 2022 and declared effective by the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) on May&nbsp;5, 2022 (the &ldquo;Registration Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering and sale of the Shares are being made pursuant to the
Sales Agreement (the &ldquo;Sales Agreement&rdquo;) dated as of June&nbsp;16, 2023, by and between the Company and BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have examined copies of the Sales Agreement, the Registration Statement,
the base prospectus that forms a part thereof and the prospectus supplement thereto related to the offering of the Shares, which prospectus
supplement is dated as of June&nbsp;16, 2023 and has been filed by the Company in accordance with Rule&nbsp;424(b)&nbsp;promulgated under
the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;). We have also examined instruments, documents and records which we deemed
relevant and necessary for the basis of our opinion hereinafter expressed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In such examination, we have assumed (i)&nbsp;the authenticity of
original documents and the genuineness of all signatures, (ii)&nbsp;the conformity to the originals of all documents submitted to us
as copies, and (iii)&nbsp;the truth, accuracy, and completeness of the information, representations and warranties contained in the records,
documents, instruments and certificates we have reviewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on and subject to the foregoing, we are of the opinion that
the Shares have been duly authorized by the Company and, when issued and delivered by the Company against payment therefor in accordance
with the terms of the Sales Agreement, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We express no opinion as to the laws of any other jurisdiction other
than the federal laws of the United States of America and the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">austin
 &nbsp;&nbsp;&nbsp;&nbsp;beijing &nbsp;&nbsp;&nbsp;&nbsp;boston &nbsp;&nbsp;&nbsp;&nbsp;BOULDER &nbsp;&nbsp;&nbsp;&nbsp;brussels &nbsp;&nbsp;&nbsp;&nbsp;hong kong &nbsp;&nbsp;&nbsp;&nbsp;london &nbsp;&nbsp;&nbsp;&nbsp;los angeles &nbsp;&nbsp;&nbsp;&nbsp;new york &nbsp;&nbsp;&nbsp;&nbsp;palo alto<BR>
SALT LAKE CITY &nbsp;&nbsp;&nbsp;&nbsp;san diego&nbsp;&nbsp;&nbsp;&nbsp; san francisco&nbsp;&nbsp;&nbsp;&nbsp; seattle&nbsp;&nbsp;&nbsp;&nbsp; shanghai &nbsp;&nbsp;&nbsp;&nbsp;washington, dc &nbsp;&nbsp;&nbsp;wilmington, de</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2318809d2_ex5-1img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edgewise Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June&nbsp;16,
</FONT>2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use of this opinion as an exhibit to the
Company&rsquo;s Current Report on Form&nbsp;8-K, filed on or about June&nbsp;16, 2023, for incorporation by reference into the Registration
Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7
of the Act or the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Wilson Sonsini Goodrich&nbsp;&amp; Rosati</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Professional Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ewtx-20230615.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6PebOdzZR+eYkxtmB7bYm6zyEpJGHj5yker5FGURoH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ewtx="http://edgewisetx.com/20230615" elementFormDefault="qualified" targetNamespace="http://edgewisetx.com/20230615">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://edgewisetx.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ewtx-20230615_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ewtx-20230615_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ewtx-20230615_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ewtx-20230615_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://edgewisetx.com/role/Cover" xlink:href="ewtx-20230615.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://edgewisetx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2318809d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2318809d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) )\# 2(  A$! Q$!_\0
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MKC/BQIE]JW@>6UT^UENK@SQL(XE+-@'DXK%.\[G7.'+1<5V'?"7_ ))CH_\
MVV_]'/7GOQ=_Y*GH?_7M;_\ H^2O2_AG87>F?#W2[.^MY+>YC\W?%*NUES*Y
M&1]"#7"_%;PWX@U/QOI^I:1I<UW';VD8W*,KO61VP>?<?G5Q:]H_F95$_8)6
M['LU-=$DC:.159&!#*PR"#V(KR7_ (3#XK_]"C9_]^)/_CM>G2_VC<:'_H[P
MVVHR0 JTD99(Y".<KGU]_P ZR<6CHC44MD_N/(M8^$_B#0=7DU3P5J# ,3M@
M\WRI4!_A#'Y67ZD=NO6I_"7Q0U^#Q/!X<\6VF)II5@64P^7*CMPNY1P5)(Y
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M-*[BG[R?JCOOA=\0M1\3W=UHVLQ+]OMHC*)E3874,%8.O0,"PZ8^G'.%\?\
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F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2318809d2_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2318809d2_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H %@# 2(  A$! Q$!_\0
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(OJQI)*R/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140341411583872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Edgewise Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001710072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1725586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1715
38th St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">262-7002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EWTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>tm2318809d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ewtx-20230615.xsd" xlink:type="simple"/>
    <context id="From2023-06-15to2023-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001710072</identifier>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-06-15to2023-06-15">0001710072</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-06-15to2023-06-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-06-15to2023-06-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-06-15to2023-06-15">2023-06-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-06-15to2023-06-15">Edgewise Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-06-15to2023-06-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-06-15to2023-06-15">001-40236</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-06-15to2023-06-15">82-1725586</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-06-15to2023-06-15">1715 38th St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-06-15to2023-06-15">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-06-15to2023-06-15">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-06-15to2023-06-15">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-06-15to2023-06-15">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-06-15to2023-06-15">262-7002</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-06-15to2023-06-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-06-15to2023-06-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-06-15to2023-06-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-06-15to2023-06-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-06-15to2023-06-15">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-15to2023-06-15">EWTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-15to2023-06-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-06-15to2023-06-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-06-15to2023-06-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    (  J!T%8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "H'05@T62ACN
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ "H'05IE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  *@=!6B+3Z^GH$   N$0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ "H'05I^@&_"Q @  X@P   T              ( !O0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  *@=!6EXJ[',     3 @  "P
M        @ &9#P  7W)E;',O+G)E;'-02P$"% ,4    "  *@=!6JL0B%C,!
M   B @  #P              @ &"$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ "H'05B0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "H'05F60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2318809d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://edgewisetx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2318809d2_8k.htm">tm2318809d2_8k.htm</File>
    <File>ewtx-20230615.xsd</File>
    <File>ewtx-20230615_lab.xml</File>
    <File>ewtx-20230615_pre.xml</File>
    <File>tm2318809d2_ex1-1.htm</File>
    <File>tm2318809d2_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2318809d2_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2318809d2_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ewtx-20230615_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ewtx-20230615_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ewtx-20230615.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ewtx",
   "nsuri": "http://edgewisetx.com/20230615",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2318809d2_8k.htm",
      "contextRef": "From2023-06-15to2023-06-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://edgewisetx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2318809d2_8k.htm",
      "contextRef": "From2023-06-15to2023-06-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://edgewisetx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-23-072232-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-072232-xbrl.zip
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MAC@$'K]10>,G%85T6'FUS!M-7SG=L R+? Z[L+50@,XM/8#-)C6&*"!:[,X
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M[H+&,>>6VM#6],QJ,<"'7L@'6C+IW8A!!ODO,(=-?2+'O7LH.?*2\N0+<#
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M=QW''V4Y:(J<3K ?XMWT<Y@^^<K/HMLZ)'48/O*AS+%H0E7'*W63)9 =Q!H
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M,>K8U0WR>[&0W\-7!'N?'H?))=@-M'WA[AA0\N::CZFHNSR7@[C.LZ8BDY.
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M%J]W$U<HMW%_]Q8V3,8X8CY.ZC:&5BC782YHF*38,,HVW*DGQ -B"'V\!]4
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MITVZ!KLT-8<"V6[\-,;5D;6#(C,H>IBL%7.QM5#6H*D*6T1R,AMO?\9FED%
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MXZ)_2RSXIS85O0C@T"M_Z2JQN/6(K5.*#SDJ(XI@HVV(Q?V^_GP:_)!X3&.
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MIU,PXV;A0@/2+QH;-N2 H<5,NH1Y%#@1G)KG.XDZ6AKVD[G?O$^T-OY1W2W
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M8L*7HRLI)<),Y[%UF;\-EC?\\OOO[B=FTE.:+S:W- YJ2(]P&5[0AO<]9LV
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M=.%-CY\TB0D>^^J=ZH(<UZ/-[1;EF,;MRB5Z'!E+J !1?=2*>QVVQKT5\&"
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M9;I#VS:6I=-3!UH5+""''C4V5RV7U+9 #:F&CG+MM^Z:;^<U!>9ER^ F-(W
MF?Y!;F_:L8 ?3%-"W5A([E/_&&N3!!47#(S/6H&_%U+4SC#YK<3?C.&+(%6A
M'::P3DKMTI4V_,XE"#O>(,3WVY%C#-'0C&]C94UCL.]NN646I3@($DB*28QL
MEI3O*(#WVT^*Y.IAL;RU)PLQQYJP@[XAE+@NZ70%QAN*9M+5C9K!</->.>I8
M2,,ISW56^+(A:<Z>V;I1N,/!I9O$20Z"3=4\E\$2>7G:WW.KXDIEY^(XN!D/
M)6-+>86*A0A1#Q)K1T)30Z-P6P(FN*O[X1VW?DL.=^)C=X<>P Z92>\Q#K7A
M.*RD\6+N[^F W!9-"6!'%(/.N7)U*6:F38S?W</T(V<:"_>2$?E14G4MMH-2
M@6 X ]_.<+\\>?KLY3GV8Y9.Y$^XB20\TC<#2]E>")X':J98.=%C!5V1],#(
M_N/T)#TY.>&B7'RAPD*T36C3O58@Q[U749EF8IAL1<G2Z)'?W:='CJQP_A:V
MLL5"[N\Y^?E+60,'%[? 'A@<X;_]]%N3*W*!6*Q'#&OM3?4L;]VE/6+K:._+
M)XVL5XZN(]J6PB7W&P<@]&['0A/WUUBIXI97RJV709D])POJ5;:,\C9L>^"
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M&!EA$9TFAI@5J^5^&,N/Y[@_.KC]TF(Y*KA4PSO0)J!?.?46Y\LK21?1-E"
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M8VGT8,T[K;/"(Z-3BY8H6)=BL>!<QRU)B\5U=7LN2,8 >-$]0VH4P'#!H4;
MQZPI&NM:6/S9"%!K18M.-ZKL^>7MT)/F^^SN.'YTHK>[RB?5;&J=^B$'F'\
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MSK9PNH6=MC'X[QPSKY/LFI!U8B>0^)4VB7&1Z:]JJLS.J)B<DI1GEFT,.PT
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M;Z'J&[&BD95U&Q5CI"IK:0-R/IWS7K0;C%>ER#N##:)K-GO'<@*BCSTI()R
MHE8%EI.4)^G7YB46L,Z7/'+O3MRW%:WX_$J#9LR.0)&.W*RAJ$8O,PO=K4"!
M<6@7-=]!IR"@1LC#V,=H\YO(*E&#$/IT:!6 G#N7GD=Z?N)66H^&0^=,[T<
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M_74M0,)#A820*C>P&G;[(];O_G;%+GJCSVM/&=@LVMFI6@? "&("Q?C2^-^
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M,#(S,#8Q-2YX<V102P$"% ,4    "  *@=!6/1=K*?\*  !LAP  %0
M        @ %M P  97=T>"TR,#(S,#8Q-5]L86(N>&UL4$L! A0#%     @
M"H'05N$^I%%7!P  Q5@  !4              ( !GPX  &5W='@M,C R,S V
M,35?<')E+GAM;%!+ 0(4 Q0    (  J!T%:U&M,S(Q@  &V"   2
M      "  2D6  !T;3(S,3@X,#ED,E\X:RYH=&U02P$"% ,4    "  *@=!6
M]&2*_+:M  !5M@, %0              @ %\+@  =&TR,S$X.# Y9#)?97@Q
M+3$N:'1M4$L! A0#%     @ "H'05DG[#BG&"   <2(  !4
M ( !9=P  '1M,C,Q.#@P.60R7V5X-2TQ+FAT;5!+!08     !@ & (L!  !>
%Y0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
